Document And Entity Information
Document And Entity Information - USD ($) $ in Billions | 12 Months Ended | ||
Dec. 31, 2021 | Feb. 10, 2022 | Jun. 30, 2021 | |
Entity Information [Line Items] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2021 | ||
Document Transition Report | false | ||
Entity File Number | 0-15386 | ||
Entity Registrant Name | CERNER CORPORATION | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Address, Address Line One | 2800 Rock Creek Parkway | ||
Entity Address, City or Town | North Kansas City, | ||
Entity Address, State or Province | MO | ||
Entity Tax Identification Number | 43-1196944 | ||
Entity Address, Postal Zip Code | 64117 | ||
City Area Code | 816 | ||
Local Phone Number | 221-1024 | ||
Title of 12(b) Security | Common Stock, $0.01 par value per share | ||
Trading Symbol | CERN | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Entity Shell Company | false | ||
Entity Public Float | $ 20.9 | ||
Entity Common Stock, Shares Outstanding | 293,344,090 | ||
Documents Incorporated by Reference | DOCUMENTS INCORPORATED BY REFERENCE Document Parts into Which Incorporated Portions of the registrant's Proxy Statement for the 2022 Annual Shareholders' Meeting Part III | ||
Entity Central Index Key | 0000804753 | ||
Amendment Flag | false | ||
Document Fiscal Year Focus | 2021 | ||
Document Fiscal Period Focus | FY | ||
Current Fiscal Year End Date | --12-31 |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2021 | |
Auditor [Line Items] | |
Auditor Name | KPMG LLP |
Auditor Location | Kansas City, Missouri |
Auditor Firm ID | 185 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 589,847 | $ 615,615 |
Short-term investments | 252,622 | 442,473 |
Receivables, net | 1,161,361 | 1,168,712 |
Inventory | 28,159 | 23,027 |
Prepaid expenses and other | 417,465 | 401,160 |
Total current assets | 2,449,454 | 2,650,987 |
Property and equipment, net | 1,656,171 | 1,804,083 |
Right-of-use assets | 82,940 | 104,536 |
Software development costs, net | 1,000,357 | 1,009,349 |
Goodwill | 1,131,121 | 914,520 |
Intangible assets, net | 458,482 | 329,249 |
Long-term investments | 461,984 | 510,220 |
Other assets | 193,649 | 198,152 |
Total assets | 7,434,158 | 7,521,096 |
Current liabilities: | ||
Accounts payable | 329,582 | 235,755 |
Long-term Debt, Current Maturities | 225,000 | 0 |
Deferred revenue | 531,234 | 393,293 |
Accrued payroll and tax withholdings | 317,092 | 309,814 |
Other current liabilities | 223,350 | 229,764 |
Total current liabilities | 1,626,258 | 1,168,626 |
Long-term debt | 1,611,256 | 1,336,069 |
Deferred Income Taxes, Noncurrent | 395,177 | 376,035 |
Other liabilities | 121,005 | 157,799 |
Total liabilities | 3,753,696 | 3,038,529 |
Shareholders' Equity: | ||
Common stock, $0.01 par value, 500,000,000 shares authorized, 380,232,975 shares issued at December 31, 2021 and 373,224,832 shares issued at December 31, 2020 | 3,802 | 3,732 |
Additional paid-in capital | 2,717,244 | 2,288,806 |
Retained earnings | 6,751,692 | 6,475,551 |
Treasury stock, 87,383,166 shares at December 31, 2021 and 67,371,686 shares at December 31, 2020 | (5,664,718) | (4,164,718) |
Accumulated other comprehensive loss, net | (127,558) | (120,804) |
Total shareholders' equity | 3,680,462 | 4,482,567 |
Total liabilities and shareholders' equity | $ 7,434,158 | $ 7,521,096 |
Common Stock, par value | $ 0.01 | |
Common Stock, Shares Authorized | 500,000,000 | |
Common stock, shares issued | 380,232,975 | 373,224,832 |
Treasury stock, shares | 87,383,166 | 67,371,686 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2021 | Dec. 31, 2020 |
Common stock, par value | $ 0.01 | |
Common stock, shares authorized | 500,000,000 | |
Common stock, shares issued | 380,232,975 | 373,224,832 |
Treasury stock, shares | 87,383,166 | 67,371,686 |
Consolidated Statements Of Oper
Consolidated Statements Of Operations - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Revenues: | |||
Revenue | $ 5,764,824 | $ 5,505,788 | $ 5,692,598 |
Costs and expenses: | |||
Cost of Revenue | 1,001,017 | 932,941 | 1,071,041 |
Sales and client service | 2,636,205 | 2,582,615 | 2,675,337 |
Software development (Includes amortization of $261,798, $247,313 and $227,414, respectively) | 835,995 | 749,007 | 737,136 |
General and administrative | 520,667 | 491,586 | 520,598 |
Amortization of acquisition-related intangibles | 62,664 | 55,595 | 87,817 |
Total costs and expenses | 5,056,548 | 4,811,744 | 5,091,929 |
Gain on sale of businesses | 0 | 220,523 | 0 |
Operating earnings | 708,276 | 914,567 | 600,669 |
Other income, net | (8,816) | 76,906 | 53,843 |
Earnings before income taxes | 699,460 | 991,473 | 654,512 |
Income taxes | (143,864) | (211,385) | (125,058) |
Net earnings | $ 555,596 | $ 780,088 | $ 529,454 |
Basic earnings per share | $ 1.86 | $ 2.54 | $ 1.66 |
Diluted earnings per share | $ 1.84 | $ 2.52 | $ 1.65 |
Basic weighted average shares outstanding | 298,725 | 306,669 | 318,229 |
Diluted weighted average shares outstanding | 301,273 | 309,136 | 321,235 |
Consolidated Statements Of Op_2
Consolidated Statements Of Operations (Parenthetical) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Income Statement [Abstract] | |||
Software development, amortization | $ 261,798 | $ 247,313 | $ 227,414 |
Consolidated Statements Of Comp
Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] | |||
Net earnings | $ 555,596 | $ 780,088 | $ 529,454 |
Foreign currency translation adjustment and other (net of taxes (benefit) of $(4,104), $3,250 and $(1,288), respectively) | (21,180) | 12,897 | (3,408) |
Unrealized gain (loss) on cash flow hedge (net of taxes (benefit) of $4,945, $(5,003) and $(4,137), respectively) | 14,827 | (15,210) | (12,578) |
Unrealized holding gain (loss) on available-for-sale investments (net of taxes (benefit) of $(137), $56 and $290, respectively) | (401) | 169 | 878 |
Comprehensive income | $ 548,842 | $ 777,944 | $ 514,346 |
Consolidated Statements Of Co_2
Consolidated Statements Of Comprehensive Income (Parenthetical Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] | |||
Foreign currency translation adjustment and other, taxes (benefit) | $ (4,104) | $ 3,250 | $ (1,288) |
Unrealized loss on cash flow hedge, taxes (benefit) | 4,945 | (5,003) | (4,137) |
Change in net unrealized holding gain (loss) on available-for-sale investments, taxes (benefit) | $ (137) | $ 56 | $ 290 |
Consolidated Statements Of Cash
Consolidated Statements Of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |||
Net earnings | $ 555,596 | $ 780,088 | $ 529,454 |
Adjustments to reconcile net earnings to net cash provided by operating activities: | |||
Depreciation and amortization | 718,854 | 697,423 | 687,966 |
Share-based compensation expense | 195,654 | 153,449 | 103,641 |
Provision for deferred income taxes | 7,351 | 1,502 | 51,125 |
Gain on sale of businesses | 0 | (220,523) | 0 |
Investment gains | 0 | (75,834) | (29,621) |
Asset Impairment Charges | 133,851 | 0 | 0 |
Changes in assets and liabilities (net of businesses acquired): | |||
Receivables, net | 26,000 | 3,686 | 58,113 |
Inventory | (5,131) | 960 | 1,855 |
Prepaid expenses and other | (4,560) | (51,442) | (76,748) |
Accounts payable | 42,485 | (62,663) | (8,734) |
Accrued income taxes | (4,431) | 19,995 | (4,599) |
Deferred revenue | 104,226 | 34,500 | (39,245) |
Other accrued liabilities | 1,789 | 155,564 | 39,892 |
Net cash provided by operating activities | 1,771,684 | 1,436,705 | 1,313,099 |
CASH FLOWS FROM INVESTING ACTIVITIES: | |||
Capital purchases | (289,694) | (283,981) | (471,518) |
Capitalized software development costs | (308,026) | (295,277) | (273,871) |
Purchases of investments | (615,330) | (696,548) | (364,648) |
Sales and maturities of investments | 858,932 | 333,161 | 579,755 |
Purchase of other intangibles | (29,561) | (38,243) | (35,587) |
Sale of businesses | 0 | 229,471 | 0 |
Disposition of assets held for sale | 9,349 | 0 | 0 |
Acquisition of business, net of cash acquired | (355,504) | (49,820) | (74,539) |
Net cash used in investing activities | (729,834) | (801,237) | (640,408) |
CASH FLOWS FROM FINANCING ACTIVITIES: | |||
Long-term debt issuance | 500,000 | 300,000 | 600,000 |
Repayment of long-term debt | 0 | (2,500) | 0 |
Proceeds from exercise of options | 304,078 | 253,605 | 258,036 |
Payments to taxing authorities in connection with shares directly withheld from associates | (71,837) | (23,672) | (16,601) |
Treasury stock purchases | (1,500,000) | (756,950) | (1,320,542) |
Dividends paid | (267,478) | (221,461) | (113,823) |
Other | (19,608) | (10,519) | (8,450) |
Net cash used in financing activities | (1,054,845) | (461,497) | (601,380) |
Effect of exchange rate changes on cash and cash equivalents | (12,773) | (199) | (3,594) |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | (25,768) | 173,772 | 67,717 |
Cash and cash equivalents at beginning of period | 615,615 | 441,843 | 374,126 |
Cash and cash equivalents at end of period | $ 589,847 | $ 615,615 | $ 441,843 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Retained Earnings [Member]Cumulative Effect, Period of Adoption, Adjustment | Treasury Stock [Member] | AOCI Attributable to Parent [Member] |
Balance at Dec. 29, 2018 | $ 3,622 | $ 1,559,562 | $ 5,576,525 | $ (2,107,768) | $ (103,552) | ||
Common stock, shares issued at Dec. 29, 2018 | 362,213,000 | ||||||
Increase (Decrease) in Shareholders' Equity [Roll Forward] | |||||||
Exercise of stock options | $ 54 | 241,968 | |||||
Exercise of stock options, shares | 5,422,000 | ||||||
Employee share-based compensation expense | 103,641 | ||||||
Other comprehensive income (loss) | (15,108) | ||||||
Treasury stock purchases | $ 1,300,000 | (1,300,000) | |||||
Dividends, Cash | (171,070) | ||||||
Net earnings | 529,454 | 529,454 | |||||
Balance at Dec. 28, 2019 | $ 3,676 | 1,905,171 | 5,934,909 | $ (4,606) | (3,407,768) | (118,660) | |
Common stock, shares issued at Dec. 28, 2019 | 367,635,000 | ||||||
Increase (Decrease) in Shareholders' Equity [Roll Forward] | |||||||
Exercise of stock options | $ 56 | 230,186 | |||||
Exercise of stock options, shares | 5,590,000 | ||||||
Employee share-based compensation expense | 153,449 | ||||||
Other comprehensive income (loss) | (2,144) | ||||||
Treasury stock purchases | 757,000 | (756,950) | |||||
Dividends, Cash | (234,840) | ||||||
Net earnings | 780,088 | 780,088 | |||||
Balance at Dec. 31, 2020 | $ 4,482,567 | $ 3,732 | 2,288,806 | 6,475,551 | (4,164,718) | (120,804) | |
Common stock, shares issued at Dec. 31, 2020 | 373,224,832 | 373,225,000 | |||||
Increase (Decrease) in Shareholders' Equity [Roll Forward] | |||||||
Exercise of stock options | $ 70 | 232,784 | |||||
Exercise of stock options, shares | 7,008,000 | ||||||
Employee share-based compensation expense | 195,654 | ||||||
Other comprehensive income (loss) | (6,754) | ||||||
Treasury stock purchases | $ 1,500,000 | (1,500,000) | |||||
Dividends, Cash | (279,455) | ||||||
Net earnings | 555,596 | 555,596 | |||||
Balance at Dec. 31, 2021 | $ 3,680,462 | $ 3,802 | $ 2,717,244 | $ 6,751,692 | $ (5,664,718) | $ (127,558) | |
Common stock, shares issued at Dec. 31, 2021 | 380,232,975 | 380,233,000 |
Supplemental Cash Flow Informat
Supplemental Cash Flow Information | 12 Months Ended |
Dec. 31, 2021 | |
Supplemental Cash Flow Elements [Abstract] | |
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] | Supplemental Disclosures of Cash Flow Information For the Years Ended (In thousands) 2021 2020 2019 Cash paid during the year for: Interest (including amounts capitalized of $10,954, $14,855, and $17,190, respectively) $ 46,559 $ 36,302 $ 25,639 Income taxes, net of refunds 125,553 149,059 100,004 Non-cash items: Lease liabilities recorded upon the commencement of operating leases 9,678 26,352 29,542 Financed capital purchases 7,255 22,218 12,673 |
Supplemental Cash Flow Inform_2
Supplemental Cash Flow Information details - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Supplemental Cash Flow Elements [Abstract] | |||
Interest Paid, Capitalized | $ 10,954 | $ 14,855 | $ 17,190 |
Interest paid, including amounts capitalized | 46,559 | 36,302 | 25,639 |
Income taxes paid, net of refunds | 125,553 | 149,059 | 100,004 |
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | 9,678 | 26,352 | 29,542 |
Capital Expenditures Incurred but Not yet Paid | $ 7,255 | $ 22,218 | $ 12,673 |
Basis of Presentation, Nature o
Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] | Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements include all the accounts of Cerner Corporation ("Cerner," the "Company," "we," "us" or "our") and its subsidiaries. All significant intercompany transactions have been eliminated in consolidation. The consolidated financial statements were prepared using accounting principles generally accepted in the United States of America ("GAAP"). These principles require us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results could differ from those estimates. Nature of Operations We design, develop, market, install, host and support healthcare information technology, healthcare devices, hardware and content solutions for healthcare organizations and consumers. We also provide a wide range of value-added services, including implementation and training, remote hosting, operational management services, revenue cycle services, support and maintenance, healthcare data analysis, clinical process optimization, transaction processing, employer health centers, and data-driven services that help life sciences companies with the discovery, development and deployment of therapies. Oracle Merger Agreement On December 20, 2021, we entered into an Agreement and Plan of Merger (as it may be amended or supplemented from time to time, the "Merger Agreement") with Cedar Acquisition Corporation ("Merger Subsidiary"), which is a wholly owned subsidiary of OC Acquisition LLC ("Parent"), Parent, which is a wholly owned subsidiary of Oracle Corporation ("Oracle"), and (solely with respect to performance of its obligations set forth in certain specified sections thereof) Oracle. Pursuant to the Merger Agreement, on January 19, 2022, Oracle commenced a cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of our common stock for a purchase price of $95.00 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. If the Offer is completed, Merger Subsidiary will merge with and into Cerner (the "Merger") and we will become a wholly owned indirect subsidiary of Oracle. As a result of the Merger, the shares of our common stock will cease to be publicly held. Completion of the Merger is subject to certain conditions, including but not limited to, a) shareholders holding a majority of the outstanding shares of our common stock tendering their shares in the Offer, and b) receipt of certain regulatory approvals, including the expiration or termination of the waiting periods or the obtaining of the required affirmative approvals applicable to the transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and certain foreign antitrust and foreign direct investment laws. We have agreed to various customary covenants and agreements in the Merger Agreement, including with respect to the operation of our business prior to the closing of the transaction, such as restrictions on making certain acquisitions and divestitures, entering into certain contracts, incurring certain indebtedness and making certain capital expenditures, paying dividends in excess of our regular quarterly dividend, issuing or repurchasing stock and taking other specified actions. Fiscal Period End Prior to fiscal year 2020, our fiscal year ended on the Saturday closest to December 31. Fiscal year 2019 consisted of 364 days and ended on December 28, 2019. In December 2019, our Board of Directors approved the change of our fiscal year to a calendar year, commencing with fiscal year 2020. Accordingly, our 2020 fiscal year presented herein consisted of 369 days and ended on December 31, 2020. Fiscal years subsequent to 2020 begin on January 1 and end on December 31 of each year. All references to years in these notes to consolidated financial statements ("Notes") represent the respective periods described above, unless otherwise noted. Supplemental Disclosures of Cash Flow Information For the Years Ended (In thousands) 2021 2020 2019 Cash paid during the year for: Interest (including amounts capitalized of $10,954, $14,855, and $17,190, respectively) $ 46,559 $ 36,302 $ 25,639 Income taxes, net of refunds 125,553 149,059 100,004 Non-cash items: Lease liabilities recorded upon the commencement of operating leases 9,678 26,352 29,542 Financed capital purchases 7,255 22,218 12,673 CARES Act Cash flows from operating activities in 2021 and 2020 include the impact of certain federal payroll taxes related to pay cycles in the second through fourth quarters of 2020, for which we deferred remittance to the taxing authority as permitted under the CARES Act. We remitted $38 million of such amounts to the taxing authority in December 2021 and expect to remit $38 million of remaining deferrals in December 2022, as permitted by the CARES Act. At both December 31, 2021 and December 31, 2020, $38 million of these deferred remittances were included in "Accrued payroll and tax withholdings" in our consolidated balance sheets. At December 31, 2020, an additional $38 million of deferred remittances were included in "Other liabilities" in our consolidated balance sheets. Summary of Significant Accounting Policies (a) Cash Equivalents - Cash equivalents consist of short-term debt securities with original maturities of less than 90 days. (b) Investments in Debt Securities – We account for our investments in debt securities as available-for-sale investments in accordance with Accounting Standards Codification Topic ("ASC") 320, Investments-Debt Securities . Short-term available-for-sale investments are primarily invested in time deposits, commercial paper, government and corporate bonds, with maturities of less than one year. Long-term available-for-sale investments are primarily invested in government and corporate bonds with maturities of less than two years. Available-for-sale investments are recorded at fair value with the unrealized gains and losses reflected in accumulated other comprehensive loss until realized. Realized gains and losses from the sale of available-for-sale investments, if any, are determined on a specific identification basis. Generally, premiums are amortized and discounts are accreted over the life of the security as adjustments to interest income for our investments. For investments in callable debt securities, any premiums are amortized to the earliest call date. Interest income is recognized when earned. Refer to Note (4) and Note (12) for further description of these assets and their fair value. (c) Investments in Equity Securities - We account for our investments in equity securities that give us the ability to exercise significant influence over the operating and financial policies of an investee under the equity method in accordance with ASC 323, Investments-Equity Method and Joint Ventures . Under the equity method, we recognize our share of the earnings or losses of an investee, generally on a three-month lag. Such share of the investee's earnings or losses are presented in "Other income (loss), net" in our consolidated statements of operations. We account for our investments in equity securities that do not qualify for equity method accounting in accordance with ASC 321, Investments-Equity Securities ("ASC 321"). We measure these investments at fair value with changes in fair value recognized in "Other income (loss), net" in our consolidated statements of operations for such investments with readily determinable fair values. For these investments that do not have readily determinable fair values, we measure such investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. (d) Concentrations - The majority of our cash and cash equivalents are held at three major financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally these deposits may be redeemed upon demand. (e) Inventory - Inventory consists primarily of computer hardware and sublicensed software, held for resale. Inventory is recorded at the lower of cost (first-in, first-out) or net realizable value. (f) Property and Equipment - We account for property and equipment in accordance with ASC 360, Property, Plant, and Equipment . Property, equipment and leasehold improvements are stated at cost. Depreciation of property and equipment is computed using the straight-line method over periods of one to 50 years. Amortization of leasehold improvements is computed using a straight-line method over the shorter of the lease terms or the useful lives, which range from periods of one to 15 years. (g) Goodwill - We account for goodwill under the provisions of ASC 350, Intangibles – Goodwill and Other . Goodwill is not amortized but is evaluated for impairment annually or whenever there is an impairment indicator. All goodwill is assigned to a reporting unit, where it is subject to an annual impairment assessment. Based on these evaluations, there was no impairment of goodwill in 2021, 2020 or 2019. Refer to Note (10) for more information on goodwill and other intangible assets. (h) Intangible Assets - We account for intangible assets in accordance with ASC 350, Intangibles – Goodwill and Other . Amortization of finite-lived intangible assets is computed using the straight-line method over periods of three to 30 years. (i) Income Taxes - Income taxes are accounted for in accordance with ASC 740, Income Taxes . Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Refer to Note (14) for additional information regarding income taxes. (j) Earnings per Common Share - Basic earnings per share ("EPS") excludes dilution and is computed, in accordance with ASC 260, Earnings Per Share , by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in our earnings. Refer to Note (15) for additional details of our earnings per share computations. (k) Accounting for Share-based Payments - We recognize all share-based payments to associates, directors and consultants, including grants of stock options, restricted stock, restricted stock units and performance shares, in the financial statements as compensation cost based on their fair value on the date of grant, in accordance with ASC 718, Compensation-Stock Compensation . This compensation cost is recognized over the vesting period on a straight-line basis for the fair value of awards that actually vest. Refer to Note (16) for a detailed discussion of share-based payments. (l) Voluntary Separation Benefits - We account for voluntary separation benefits in accordance with the provisions of ASC 712, Compensation-Nonretirement Postemployment Benefits . Voluntary separation benefits are recorded to expense when an associate irrevocably accepts the offer and the amount of the termination liability is reasonably estimable. In 2021, 2020 and 2019, we recognized $53 million, $20 million and $52 million, respectively, of expenses in connection with voluntary separation benefits, which are included in "General and administrative" expense in our consolidated statements of operations. (m) Exit or Disposal Cost Obligations - We account for involuntary employee separation benefits pursuant to one-time benefit arrangements and contract termination costs in accordance with ASC 420, Exit or Disposal Cost Obligations . In 2021, 2020 and 2019, we recognized $56 million, $22 million and $34 million, respectively, of expenses in connection with involuntary associate termination events, which are included in "General and administrative" expense in our consolidated statements of operations. In 2020 and 2019, we recognized $29 million and $66 million, respectively, of pre-tax charges within our Domestic segment in connection with the termination of certain contracts prior to the end of their stated terms. Such charges are included in "Sales and client service" expense in our consolidated statements of operations. (n) Foreign Currency - In accordance with ASC 830, Foreign Currency Matters , assets and liabilities of non-U.S. subsidiaries whose functional currency is the local currency are translated into U.S. dollars at exchange rates prevailing at the balance sheet date. Revenues and expenses are translated at average exchange rates during the year. The net exchange differences resulting from these translations are reported in accumulated other comprehensive loss. Gains and losses resulting from foreign currency transactions are included in the consolidated statements of operations. (o) Recently Issued Accounting Pronouncements Reference Rate Reform. The Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting in March 2020 and ASU 2021-01, Reference Rate Reform (Topic 848): Scope in January 2021. Such guidance provides optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform, such as the upcoming discontinuance of the London Interbank Offered Rate ("LIBOR"). The accommodations within this guidance may be applied prospectively from the beginning of our 2020 first quarter through December 31, 2022. We are currently evaluating the effect that this guidance may have on our contracts that reference LIBOR, specifically, our Fourth Amended and Restated Credit Agreement and related interest rate swap. As of the date of this filing, we have not elected to apply any of the provisions of this guidance. Business Combinations. The FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers in October 2021. Such guidance amends the recognition and measurement principles that apply to business combinations to require that an entity recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. ASU 2021-08 is effective for the Company in the first quarter of 2023, with early adoption permitted. The standard requires prospective application to business combinations occurring on or after the date of adoption. As of the date of this filing, we have not determined if we will early adopt. |
Description of New Accounting Pronouncements Not yet Adopted [Text Block] | Recently Issued Accounting Pronouncements Reference Rate Reform. The Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting in March 2020 and ASU 2021-01, Reference Rate Reform (Topic 848): Scope in January 2021. Such guidance provides optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform, such as the upcoming discontinuance of the London Interbank Offered Rate ("LIBOR"). The accommodations within this guidance may be applied prospectively from the beginning of our 2020 first quarter through December 31, 2022. We are currently evaluating the effect that this guidance may have on our contracts that reference LIBOR, specifically, our Fourth Amended and Restated Credit Agreement and related interest rate swap. As of the date of this filing, we have not elected to apply any of the provisions of this guidance. Business Combinations. The FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers in October 2021. Such guidance amends the recognition and measurement principles that apply to business combinations to require that an entity recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. ASU 2021-08 is effective for the Company in the first quarter of 2023, with early adoption permitted. The standard requires prospective application to business combinations occurring on or after the date of adoption. As of the date of this filing, we have not determined if we will early adopt. |
Revenue from Contract with Cust
Revenue from Contract with Customer | 12 Months Ended |
Dec. 31, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Revenue from Contract with Customer [Text Block] | Revenue Recognition Revenue Recognition Policy We recognize revenue in accordance with the guidance in ASU 2014-09 , Revenue from Contracts with Customers (Topic 606) , which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard contains a five-step process to be followed in determining the amount and timing of revenue recognition. We enter into contracts with customers that may include various combinations of our software solutions and related services, which are generally capable of being distinct and accounted for as separate performance obligations. Performance obligations that are not distinct at contract inception are combined. Contracts that include software customization may result in the combination of the customization services with the software license as one distinct performance obligation. The predominant model of customer procurement involves multiple deliverables and includes a software license agreement, project-related implementation and consulting services, software support, hosting services, and computer hardware. We allocate revenues to each performance obligation within an arrangement based on estimated relative stand-alone selling price. Revenue is then recognized for each performance obligation upon transfer of control of the software solution or services to the customer in an amount that reflects the consideration we expect to receive. Generally, we recognize revenue under Topic 606 for each of our performance obligations as follows: • Perpetual software licenses - We recognize perpetual software license revenues when control of such licenses are transferred to the client ("point in time"). We determine the amount of consideration allocated to this performance obligation using the residual approach. • Software as a service - We recognize software as a service ratably over the related hosting period ("over time"). • Time-based software and content license fees - We recognize a license component of time-based software and content license fees upon delivery to the client ("point in time") and a non-license component (i.e. support) ratably over the respective contract term ("over time"). • Hosting - Remote hosting recurring services are recognized ratably over the hosting service period ("over time"). Certain of our hosting arrangements contain fees deemed to be a "material right" under Topic 606. We recognize such fees over the term that will likely affect the client's decision about whether to renew the related hosting service ("over time"). • Services - We recognize revenue for fixed fee services arrangements over time, utilizing a labor hours input method. For fee-for-service arrangements, we recognize revenue over time as hours are worked at the rates clients are invoiced, utilizing the "as invoiced" practical expedient available in Topic 606. For stand-ready services arrangements, we recognize revenue ratably over the related service period. • Support and maintenance - We recognize support and maintenance fees ratably over the related contract period ("over time"). • Hardware - We recognize hardware revenues when control of such hardware/devices is transferred to the client ("point in time"). • Transaction processing - We recognize transaction processing revenues ratably as we provide such services ("over time"). Certain customer contracts require significant customization of the software to meet the particular requirements specified by each customer. The contract pricing is stated as a fixed amount and generally results in the transfer of control of the applicable performance obligation over time. We recognize revenue for such contracts based on the proportion of labor hours expended to the total hours expected to complete the performance obligation. The impact to revenues for changes in estimates of total hours expected to complete performance obligations are recognized in the period in which they occur, and were not material for the periods presented herein. Revenues are recognized net of any taxes collected from customers and subsequently remitted to governmental authorities. Disaggregation of Revenue The following table presents revenues disaggregated by our business models: For the Years Ended 2021 2020 2019 (In thousands) Domestic International Total Domestic International Total Domestic International Total Licensed software $ 671,926 $ 53,730 $ 725,656 $ 604,707 $ 51,512 $ 656,219 $ 628,958 $ 51,627 $ 680,585 Technology resale 163,280 21,392 184,672 173,264 23,327 196,591 225,076 21,809 246,885 Subscriptions 365,936 16,922 382,858 354,023 24,185 378,208 333,298 25,417 358,715 Professional services 1,817,213 299,278 2,116,491 1,717,873 212,572 1,930,445 1,760,532 231,946 1,992,478 Managed services 1,143,188 145,265 1,288,453 1,120,939 124,488 1,245,427 1,098,695 115,205 1,213,900 Support and maintenance 849,428 183,479 1,032,907 881,778 189,001 1,070,779 904,204 200,434 1,104,638 Reimbursed travel 33,658 129 33,787 27,185 934 28,119 87,364 8,033 95,397 Total revenues $ 5,044,629 $ 720,195 $ 5,764,824 $ 4,879,769 $ 626,019 $ 5,505,788 $ 5,038,127 $ 654,471 $ 5,692,598 The following table presents our revenues disaggregated by timing of revenue recognition: For the Years Ended 2021 2020 2019 (In thousands) Domestic International Total Domestic International Total Domestic International Total Revenue recognized over time $ 4,736,395 $ 680,557 $ 5,416,952 $ 4,557,358 $ 585,316 $ 5,142,674 $ 4,565,172 $ 600,953 $ 5,166,125 Revenue recognized at a point in time 308,234 39,638 347,872 322,411 40,703 363,114 472,955 53,518 526,473 Total revenues $ 5,044,629 $ 720,195 $ 5,764,824 $ 4,879,769 $ 626,019 $ 5,505,788 $ 5,038,127 $ 654,471 $ 5,692,598 Significant Customers Revenues attributable to our relationships (as the prime contractor or a subcontractor) with U.S. government agencies, within our Domestic segment, comprised 20%, 18% and 13% of our consolidated revenues for 2021, 2020 and 2019, respectively. Amounts due in connection with these relationships comprised 15% and 13% of client receivables as of December 31, 2021 and December 31, 2020, respectively. Transaction Price Allocated to Remaining Performance Obligations As of December 31, 2021, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts approximates $13.26 billion, of which we expect to recognize approximately 31% of the revenue over the next 12 months and the remainder thereafter. As of December 31, 2020, the aggregate amount of transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied) for executed contracts approximated $13.04 billion. Contract Liabilities Our payment arrangements with clients typically include an initial payment due upon contract signing and date-based licensed software payment terms and payments based upon delivery for services, hardware and sublicensed software. Customer payments received in advance of satisfaction of the related performance obligations are deferred as contract liabilities. Such amounts are classified in our consolidated balance sheets as "Deferred revenue". During 2021 and 2020, substantially all of our contract liability balance at the beginning of each respective year was recognized in revenues during that year. Costs to Obtain or Fulfill a Contract We have determined the only significant incremental costs incurred to obtain contracts with clients within the scope of Topic 606 are sales commissions paid to our associates. We record sales commissions as an asset, and amortize to expense ratably over the remaining performance periods of the related contracts with remaining performance obligations. As of December 31, 2021 and December 31, 2020, our consolidated balance sheets included assets of $91 million and $88 million, respectively, related to sales commissions to be expensed in future periods, which are included in "Other assets". We recognized $39 million, $38 million and $41 million of amortization related to these sales commissions assets in 2021, 2020 and 2019, respectively, which is included in "Costs of revenue" in our consolidated statements of operations. Significant Judgments when Applying Topic 606 Our contracts with clients typically include various combinations of our software solutions and related services. Determining whether such software solutions and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment. Contract transaction price is allocated to distinct performance obligations using estimated stand-alone selling price. We determine stand-alone selling price maximizing observable inputs such as stand-alone sales when they exist or substantive renewal prices charged to clients. In instances where stand-alone selling price is not observable, we utilize an estimate of stand-alone selling price. Such estimates are derived from various methods that include: cost plus margin, historical pricing practices, and the residual approach. Judgment may be required to determine standalone selling prices for each performance obligation and whether it depicts the amount we expect to receive in exchange for the related good or service. Contract modifications occur when we and our customers agree to modify existing customer contracts to change the scope or price (or both) of the contract or when a customer terminates some, or all, of the existing services provided by us. When a contract modification occurs, it requires us to exercise judgment to determine if the modification should be accounted for as (i) a separate contract, (ii) the termination of the original contract and creation of a new contract, (iii) a cumulative catch up adjustment to the original contract, or a combination thereof. The labor hours input method used for our fixed fee services performance obligation is dependent on our ability to reliably estimate the direct labor hours to complete a project, which may span several years. We utilize our historical project experience and detailed planning process as a basis for our future estimates to complete current projects. Certain of our arrangements contain variable consideration. We do not believe our estimates of variable consideration to be significant to our determination of revenue recognition. |
Receivables
Receivables | 12 Months Ended |
Dec. 31, 2021 | |
Receivables [Abstract] | |
Receivables | Receivables Client receivables primarily represent recorded revenues that have either been billed, or for which we have an unconditional right to invoice and receive payment in the future. We periodically provide long-term financing options to creditworthy clients through extended payment terms. Generally, these extended payment terms provide for date-based payments over a fixed period, not to exceed the term of the overall arrangement. Thus, our portfolio of client contracts contains a financing component, which is recognized over time as a component of "Other income (loss), net" in our consolidated statements of operations. We perform ongoing credit evaluations of our clients and generally do not require collateral from our clients. A summary of net receivables is as follows: (In thousands) 2021 2020 Client receivables $ 1,307,167 $ 1,322,278 Less: Provision for expected credit losses 145,806 153,566 Total receivables, net $ 1,161,361 $ 1,168,712 In addition to the client receivables presented above, at December 31, 2021 and December 31, 2020, we had $16 million and $17 million, respectively, of non-current net client receivables, which are presented in "Other assets" in our consolidated balance sheets. A reconciliation of the beginning and ending amount of our provision for expected credit losses is as follows: (In thousands) Current Non-current Total Provision for expected credit losses - balance at December 29, 2018 $ 64,561 $ 63,849 $ 128,410 Additions charged to costs and expenses 57,167 — 57,167 Deductions, foreign currency and other (15,653) 1,490 (14,163) Provision for expected credit losses - balance at December 28, 2019 106,075 65,339 171,414 Cumulative effect of accounting change (ASU 2016-13) 4,606 — 4,606 Additions charged to costs and expenses 65,099 20,703 85,802 Deductions, foreign currency and other (22,214) (47,478) (69,692) Provision for expected credit losses - balance at December 31, 2020 153,566 38,564 192,130 Additions charged to costs and expenses 39,791 — 39,791 Reclassifications to non-current (26,480) 26,480 — Deductions, foreign currency and other (21,071) (3,938) (25,009) Provision for expected credit losses - balance at December 31, 2021 $ 145,806 $ 61,106 $ 206,912 During 2021 and 2020, we received total client cash collections of $6.13 billion and $5.70 billion, respectively. Expected Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which provides a new impairment model for certain financial assets that is based on expected losses rather than incurred losses. Such guidance impacts how we determine our allowance for estimated uncollectible client receivables. The standard requires use of the modified retrospective (cumulative effect) transition approach as of the beginning of the first reporting period in which the guidance was effective, which for the Company was the first quarter of 2020. Under this transition method, the cumulative effect from prior periods upon applying this new guidance was recognized in our consolidated balance sheets as of December 29, 2019. We did not recast comparative periods. A summary of such cumulative effect adjustment is as follows: (In thousands) Increase/(Decrease) Receivables, net $ (4,606) Retained earnings (4,606) The cumulative effect adjustment is the result of providing an allowance on unbilled client receivables, for which we have an unconditional right to invoice and receive payment in the future. Our estimates of expected credit losses for client receivables at both December 31, 2021 and December 31, 2020, were primarily based on historical credit loss experience and adjustments for certain asset-specific risk characteristics (i.e. known client financial hardship or bankruptcy). Exposure to credit losses may increase if our clients are adversely affected by changes in healthcare laws; changes in reimbursement or payor models; economic pressures or uncertainty associated with local or global economic recessions; disruption associated with the COVID-19 pandemic; or other client-specific factors. Although we have historically not experienced significant credit losses, it is possible that there could be an adverse impact from potential adjustments to the carrying amount of client receivables as clients' cash flows are impacted by the COVID-19 pandemic and related economic uncertainty, which may be material. |
Investments
Investments | 12 Months Ended |
Dec. 31, 2021 | |
Investments [Abstract] | |
Investments | Investments Available-for-sale investments at the end of 2021 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 149,429 $ — $ — $ 149,429 Time deposits 35,342 — — 35,342 Commercial paper 77,850 — — 77,850 Government and corporate bonds 5,000 — — 5,000 Total cash equivalents 267,621 — — 267,621 Short-term investments: Time deposits 25,598 — — 25,598 Commercial paper 57,000 — (14) 56,986 Government and corporate bonds 170,123 18 (103) 170,038 Total short-term investments 252,721 18 (117) 252,622 Long-term investments: Government and corporate bonds 31,167 — (149) 31,018 Total available-for-sale investments $ 551,509 $ 18 $ (266) $ 551,261 Available-for-sale investments at the end of 2020 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 40,027 $ — $ — $ 40,027 Time deposits 36,756 — — 36,756 Commercial Paper 61,000 — — 61,000 Total cash equivalents 137,783 — — 137,783 Short-term investments: Time deposits 28,302 — — 28,302 Commercial Paper 264,000 12 (19) 263,993 Government and corporate bonds 149,975 247 (44) 150,178 Total short-term investments 442,277 259 (63) 442,473 Long-term investments: Government and corporate bonds 136,983 152 (57) 137,078 Total available-for-sale investments $ 717,043 $ 411 $ (120) $ 717,334 We sold available-for-sale investments for proceeds of $420 million, $71 million and $233 million in 2021 , 2020 and 2019, respectively, resulting in insignificant gains/losses in each period. Other Investments At December 31, 2021 and December 31, 2020, we had investments in equity securities that do not have readily determinable fair values of $406 million and $361 million, respectively, accounted for in accordance with ASC 321, Investments-Equity Securities . Such investments are included in "Long-term investments" in our consolidated balance sheets. We did not record any changes in the measurement of such investments in 2021, 2020, or 2019, respectively. At December 28, 2019, we had investments in equity securities with readily determinable fair values of $14 million, accounted for in accordance with ASC 321. Such investments were included in "Short-term investments" in our consolidated balance sheets. Changes in the measurement of such investments favorably impacted "Other income (loss), net" by $76 million and $14 million in 2020 and 2019, respectively. In August 2020, we sold these investments for cash proceeds of $90 million. At December 31, 2021 and December 31, 2020, we had investments in equity securities reported under the equity method of accounting of $25 million and $12 million, respectively. Such investments are included in "Long-term investments" in our consolidated balance sheets. Impairment Assessment We adopted ASU 2016-13 in the first quarter of 2020, which made certain amendments to the model used to assess available-for-sale debt securities for impairment. Such guidance provides that an available-for-sale debt security is impaired if the fair value of the security is less than its amortized cost basis. A determination is made whether the decline in fair value below the amortized cost basis has resulted from a credit loss or other factors, such as market liquidity or changes in interest rates. Impairment related to credit losses is recognized in net earnings, whereas impairment related to other factors is recognized as a component of accumulated other comprehensive loss, net. We did not recognize any impairment on our available-for-sale debt securities through net earnings in 2021 or 2020. |
Property and Equipment
Property and Equipment | 12 Months Ended |
Dec. 31, 2021 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment | Property and Equipment A summary of property, equipment and leasehold improvements stated at cost, less accumulated depreciation and amortization, is as follows: (In thousands) Depreciable Lives (Yrs) 2021 2020 Held and used: Computer and communications equipment 1 — 5 $ 1,981,488 $ 1,939,517 Land, buildings and improvements 12 — 50 1,180,042 1,403,835 Leasehold improvements 1 — 15 202,283 208,496 Furniture and fixtures 5 — 12 116,236 146,351 Other equipment 3 — 20 20,444 1,025 3,500,493 3,699,224 Less accumulated depreciation and leasehold amortization 1,933,623 1,895,141 Property and equipment held and used 1,566,870 1,804,083 Assets held for sale 89,301 — Property and equipment, net $ 1,656,171 $ 1,804,083 Depreciation Expense Depreciation and leasehold amortization expense for 2021, 2020 and 2019 was $362 million, $365 million and $347 million, respectively. Real Estate Held For Sale In connection with our operational improvement initiatives, during 2021, we made certain decisions regarding the continued use of certain of our owned real estate. As a result of those decisions, on July 9, 2021, we sold office space located in Kansas City, Missouri (known as our Oaks Campus), in April 2021 began the process of marketing office space located in Kansas City, Missouri (known as our Riverport Campus), in June 2021 began the process of marketing office |
Leases
Leases | 12 Months Ended |
Dec. 31, 2021 | |
Leases [Abstract] | |
Lessee, Operating Leases [Text Block] | Leases In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) , which introduced a new accounting model that requires most leases to be reported on the balance sheet. It also established disclosure requirements, which are more extensive than those required under prior U.S. GAAP. The standard required use of the modified retrospective (cumulative effect) transition approach and was effective for the Company in the first quarter of 2019. We selected the effective date of ASU 2016-02 as the date of initial application on transition, as permitted by ASU 2016-02, as amended ("Topic 842"). Under this transition method, the cumulative effect from prior periods upon applying the new guidance to arrangements containing leases was recognized in our consolidated balance sheets as of December 30, 2018. We did not recast comparative periods. A summary of such cumulative effect adjustment is as follows: (In thousands) Increase / Right-of-use asset $ 129,652 Prepaid expenses and other 3,968 Other current liabilities 22,767 Other liabilities 110,853 Arrangements Containing Leases The cumulative effect adjustment above, is primarily comprised of arrangements where we are the lessee under operating leases for real estate (office, data center, and warehouse space) and certain dedicated fiber optic lines within our infrastructure. The duration of these agreements ranges from several months to in excess of 20 years. Generally, variable lease payments under these operating lease agreements relate to amounts based on changes to an index or rate (i.e. percentage change in the consumer price index). We do not have any arrangements where we are the lessee, classified as finance leases in our consolidated financial statements. In addition to the items described above, we also procure hotel stays and rental cars in connection with associate business travel, and the use of certain equipment for trade shows, client presentations, conferences, and internal meetings. We have made the policy election to classify such arrangements as short-term leases, as defined in Topic 842. As such, we have not recognized lease liabilities and right-of-use assets for such arrangements in our consolidated financial statements. The duration of these arrangements is less than one month. Therefore, we do not disclose any short-term lease expense, as permitted by Topic 842. Expense for such items is recognized on a straight-line basis over the term of such arrangements. Arrangements in which we are the lessor are not significant to our consolidated financial statements. Amounts Included in the Consolidated Financial Statements The following table presents a summary of lease liability and right-of-use asset amounts included in our consolidated balance sheets at the end of 2021 and 2020, under operating lease arrangements where we are the lessee: (In thousands) Description Balance Sheet Classification 2021 2020 Right-of-use asset Right-of-use assets $ 82,940 $ 104,536 Lease liability - current Other current liabilities 27,694 29,913 Lease liability - non-current Other liabilities 67,160 90,106 Operating lease cost for 2021, 2020 and 2019 was $31 million, $37 million, and $37 million, respectively. Variable lease cost was less than $1 million in each of 2021, 2020 and 2019. Maturity Analysis Aggregate future payments under operating lease arrangements where we are the lessee (by fiscal year) are as follows: (In thousands) Operating Lease Obligations 2022 $ 27,694 2023 20,826 2024 13,824 2025 8,884 2026 5,978 2027 and thereafter 32,031 Aggregate future payments 109,237 Impact of discounting (14,383) Aggregate lease liability at December 31, 2021 $ 94,854 At December 31, 2021, the weighted-average remaining lease term and weighted-average discount rate for our operating lease arrangements where we are the lessee were 6.97 years and 3.3%, respectively. |
Software Development Costs
Software Development Costs | 12 Months Ended |
Dec. 31, 2021 | |
Research and Development [Abstract] | |
Software Development Costs | Software Development Our software solutions are offered to our clients both through traditional licenses as well as software as a service delivery models. Development costs associated with the certain solutions offered exclusively through a software as a service model are accounted for in accordance with ASC 350-40, Internal-Use Software . All other client solution development costs, which represent a significant majority of development costs, are accounted for in accordance with ASC 985-20, Costs of Software to be Sold, Leased or Marketed . Under ASC 985-20, software development costs incurred in creating computer software solutions are expensed until technological feasibility has been established upon completion of a detailed program design. Thereafter, all software development costs incurred through the software's general release date are capitalized and subsequently recorded at the lower of amortized cost or net realizable value. Capitalized costs are amortized based on current and expected future revenue for each software solution with minimum annual amortization equal to the straight-line amortization over the estimated economic life of the solution. We amortize capitalized costs over five years. Under ASC 350-40, software development costs related to preliminary project activities and post-implementation and maintenance activities are expensed as incurred. We capitalize direct costs related to application development activities that are probable to result in additional functionality. Capitalized costs are amortized on a straight-line basis over five years. We test for impairment whenever events or changes in circumstances that could impact recoverability occur. A summary of software development costs, net is as follows: 2021 2020 (In thousands) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Software to be sold, leased or marketed $ 2,751,960 $ 1,985,051 $ 2,610,476 $ 1,788,019 Software delivered exclusively as a service 474,712 241,264 385,168 198,276 Total $ 3,226,672 $ 2,226,315 $ 2,995,644 $ 1,986,295 Software development costs, net $ 1,000,357 $ 1,009,349 Estimated aggregate amortization expense for each of the next five years is as follows: (In thousands) 2022 $ 280,626 2023 247,172 2024 201,507 2025 146,610 2026 90,212 Information regarding our software development costs is included in the following table: For the Years Ended (In thousands) 2021 2020 2019 Software development costs $ 828,502 $ 796,971 $ 783,593 Capitalized software development costs (308,026) (295,277) (273,871) Amortization of capitalized software development costs 261,798 247,313 227,414 Net realizable value charges 53,721 — — Total software development expense $ 835,995 $ 749,007 $ 737,136 In 2021, we recorded pre-tax charges of $54 million to reduce the carrying amount of certain capitalized software development costs to estimated net realizable value. |
Business Acquisition
Business Acquisition | 12 Months Ended |
Dec. 31, 2021 | |
Business Combinations [Abstract] | |
Business Combination Disclosure [Text Block] | Business Acquisitions 2021 Acquisition On April 1, 2021, we acquired Kantar Health, a division of Kantar Group. Kantar Health provides data, analytics, commercial research, and consulting services to the life sciences industry. We believe this acquisition complements our existing Data-as-a-Service efforts as it provides a meaningful entry into the pharmaceutical market through Kantar Health's existing clients and their leadership team with important industry experience and relationships. These factors, combined with the synergies and economies of scale expected, are the basis for the acquisition and comprise the resulting goodwill recorded. Consideration for the acquisition was a base cash purchase price of $375 million. The base purchase price was subject to post-closing adjustments for working capital and certain other adjustments, as specified in the Securities Purchase Agreement dated December 16, 2020, as amended. Our acquisition of Kantar Health was treated as a purchase in accordance with ASC 805, Business Combinations ("ASC 805"), which requires allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed in the transaction. The final allocation of purchase price was as follows: (In thousands) Allocation Amount Cash and cash equivalents $ 15,311 Receivables, net 32,616 Prepaid expenses and other 8,881 Property and equipment, net 1,198 Right-of-use assets 1,939 Goodwill 226,232 Intangible assets, net: Customer relationships 143,100 Existing technologies 39,700 Trade names 10,200 Other assets 428 Accounts payable (36,748) Deferred revenue (35,698) Accrued payroll and tax withholdings (11,172) Other current liabilities (3,189) Deferred income taxes (11,733) Other liabilities (10,250) Total purchase price $ 370,815 The fair values of the acquired intangible assets were estimated by applying the income approach. Such estimations required the use of inputs that were unobservable in the marketplace (Level 3), including a discount rate that we estimated would be used by a market participant in valuing these assets, projections of revenues and cash flows, and client attrition rates, among others. The acquired intangible assets are being amortized over a weighted-average period of 13 years. Refer to Note (12) for further information about the fair value level hierarchy. The goodwill of $226 million was allocated among our Domestic and International operating segments, as shown in Note (10), with approximately $170 million of such goodwill expected to be deductible for tax purposes. Our consolidated statement of operations for the year ended December 31, 2021 includes revenues of $148 million attributable to the acquired business since the April 1, 2021 acquisition date. The earnings contribution from the acquired business for the year ended December 31, 2021 was not material to our consolidated financial statements. Pro forma results of operations, assuming the acquisition was made at the beginning of the earliest period presented, have not been presented because the effect of this acquisition was not material to our results. 2020 Acquisitions On April 1, 2020, we acquired a consulting company specializing in providing cybersecurity solutions to clients in the healthcare industry, for cash consideration of $34 million. We believe this acquisition enhanced our resource capabilities and growth opportunities for our cybersecurity solution offerings. These factors, combined with the synergies and economies of scale expected, are the basis for the acquisition and comprise the resulting goodwill recorded. On October 19, 2020, we acquired a software company that offered a patient referral management solution to clients within the healthcare industry, for cash consideration of $15 million. We believe this acquisition enhanced our portfolio of offerings on our HealtheIntent platform. This factor, combined with the synergies and economies of scale expected, are the basis for the acquisition and comprise the resulting goodwill recorded. These acquisitions were treated as purchases in accordance with ASC 805, which requires allocation of the purchase price to the estimated fair values of assets and liabilities acquired in the transactions. The aggregate final allocation of purchase price for our 2020 acquisitions was as follows: (In thousands) Allocation Amount Receivables, net $ 2,313 Inventory 863 Prepaid expenses and other 331 Property and equipment, net 114 Right-of-use assets 683 Goodwill 33,709 Intangible assets, net 16,510 Other assets 179 Accounts payable (880) Deferred revenue (3,158) Accrued payroll and tax withholdings (501) Other current liabilities (713) Deferred income taxes (374) Total purchase price $ 49,076 The goodwill was allocated to our Domestic operating segment, with $4 million of such goodwill expected to be deductible for tax purposes. Identifiable intangible assets primarily consist of acquired technology intangible assets and are being amortized over a weighted-average period of 8 years. The operating results from of our 2020 acquisitions were combined with our operating results subsequent to the respective purchase dates. Pro-forma results of operations, assuming these acquisitions were made at the beginning of the earliest period presented, have not been presented because the effect of these acquisitions, both individually and in the aggregate, were not material to our results. 2019 Acquisition On October 25, 2019, we acquired all of the issued and outstanding membership interests of AbleVets, LLC, a Virginia limited liability company ("AbleVets"), for cash consideration of $76 million. AbleVets is a health IT engineering and consulting company specializing in cybersecurity, cloud and system development solutions for federal organizations. We believe this acquisition enhanced our resource capabilities and growth opportunities within our federal business. These factors, combined with the synergies and economies of scale expected from combining the operations of AbleVets with Cerner, are the basis for the acquisition and comprise the resulting goodwill recorded. The acquisition of AbleVets was treated as a purchase in accordance with ASC 805, which requires allocation of the purchase price to the estimated fair values of assets and liabilities acquired in the transaction. The final allocation of purchase price was as follows: (In thousands) Allocation Amount Cash and cash equivalents $ 471 Receivables, net 11,690 Prepaid expenses and other 911 Property and equipment, net 1,240 Right-of-use assets 8,448 Goodwill 37,815 Intangible assets, net 37,402 Accounts payable (5,244) Deferred revenue (157) Accrued payroll and tax withholdings (5,812) Other current liabilities (2,994) Other liabilities (8,016) Total purchase price $ 75,754 The fair values of the acquired intangible assets were estimated by applying the income approach. Such estimations required the use of inputs that were unobservable in the marketplace (Level 3), including a discount rate that we estimated would be used by a market participant in valuing these assets, projections of revenues and cash flows, and client attrition rates, among others. Refer to Note (12) for further information about the fair value level hierarchy. The goodwill was allocated to our Domestic operating segment and is expected to be deductible for tax purposes. Identifiable intangible assets primarily consist of customer relationship intangible assets and are being amortized over a weighted-average period of 8 years. The operating results of AbleVets were combined with our operating results subsequent to the purchase date of October 25, 2019. Pro-forma results of operations, assuming this acquisition was made at the beginning of the earliest period presented, have not been presented because the effect of this acquisition was not material to our results. |
Gain on sale of businesses
Gain on sale of businesses | 12 Months Ended |
Dec. 31, 2021 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Disposal Groups, Including Discontinued Operations, Disclosure | Gain on Sale of Businesses Germany and Spain On July 1, 2020, we sold certain of our business operations, primarily conducted in Germany and Spain, to affiliates of CompuGroup Medical SE & Co. KGaA ("CGM"), as a part of our portfolio management strategy. Such operations included the associates, intellectual property, client contracts, other assets, and liabilities related to our medico ® , Selene ® , Soarian Health Archive ® , and Soarian ® Integrated Care solution offerings. We received a sale price of $230 million, which was subject to post-closing adjustments for working capital and certain other adjustments. The following table presents a reconciliation of the sale price to the net gain recognized on the disposed business operations which is included in "Gain on sale of businesses" in our consolidated statements of operations: (In thousands) Sale price $ 230,316 Net assets/liabilities removed (7,934) Transaction expenses (5,583) Foreign currency 1,550 Gain on sale of businesses $ 218,349 The following table presents a reconciliation of the sale price to the cash proceeds received from CGM which are included in "Sale of businesses" in our consolidated statements of cash flows: (In thousands) Sale price $ 230,316 Receivable due from CGM (4,049) VAT and other transaction taxes, net (2,142) Foreign currency 356 Cash received from sale of businesses $ 224,481 Amounts included in our consolidated balance sheets related to the disposed business operations immediately prior to the sale on July 1, 2020 were as follows: (In thousands) Asset/(Liability) Receivables, net $ 8,646 Inventory 65 Prepaid expenses and other 5,993 Property and equipment, net 340 Right-of-use assets 554 Software development costs, net 5,532 Goodwill 7,692 Intangible assets, net 3,687 Accounts payable (2,763) Deferred revenue (16,756) Accrued payroll and tax withholdings (4,545) Other current liabilities (511) Net assets/(liabilities) $ 7,934 Revenue Cycle Outsourcing On August 3, 2020, we sold certain of our revenue cycle outsourcing business operations to affiliates of R1 RCM Inc., as a part of our portfolio management strategy. Such operations included the associates, client contracts, certain other assets, and certain liabilities related to our commercial revenue cycle outsourcing services business. A net gain of $2 million was recognized on the disposed business operations and is included in "Gain on sale of businesses" in our consolidated statements of operations. Amounts included in our consolidated balance sheets related to the disposed business operations immediately prior to the sale on August 3, 2020 were not material to our consolidated financial statements. |
Goodwill and Other Intangible A
Goodwill and Other Intangible Assets | 12 Months Ended |
Dec. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Intangible Assets Disclosure [Text Block] | Goodwill and Other Intangible Assets The changes in the carrying amounts of goodwill by segment were as follows: (In thousands) Domestic International Total Balance at the end of 2019 $ 819,735 $ 63,423 $ 883,158 Purchase price allocation adjustments for the AbleVets acquisition 744 — 744 Goodwill recorded in connection with 2020 business acquisitions 33,709 — 33,709 Goodwill reduction in connection with divestiture transactions — (7,692) (7,692) Foreign currency translation adjustment and other — 4,601 4,601 Balance at the end of 2020 854,188 60,332 914,520 Goodwill recorded in connection with the Kantar Health acquisition 119,709 106,523 226,232 Foreign currency translation adjustment and other — (9,631) (9,631) Balance at the end of 2021 $ 973,897 $ 157,224 $ 1,131,121 A summary of net intangible assets is as follows: 2021 2020 (In thousands) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Customer lists $ 636,410 $ 360,598 $ 494,615 $ 312,044 Purchased software 396,508 346,381 354,228 337,811 Internal use software 233,438 150,356 207,696 123,280 Trade names 52,883 33,719 42,951 28,961 Other 52,179 21,882 50,535 18,680 Total $ 1,371,418 $ 912,936 $ 1,150,025 $ 820,776 Intangible assets, net $ 458,482 $ 329,249 Amortization expense for 2021, 2020 and 2019 was $95 million, $85 million and $114 million, respectively. Estimated aggregate amortization expense for each of the next five years is as follows: (In thousands) 2022 $ 96,281 2023 86,863 2024 79,985 2025 38,916 2026 20,769 |
Indebtedness
Indebtedness | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
Indebtedness | Long-term Debt The following is a summary of indebtedness outstanding: (In thousands) 2021 2020 Credit agreement loans due December 30, 2026 $ 600,000 $ 600,000 Senior notes: Series 2021-A due March 24, 2026 100,000 — Series 2021-B due March 24, 2031 400,000 — Series 2020-A due March 11, 2030 300,000 300,000 Series 2015-A due February 15, 2022 225,000 225,000 Series 2015-B due February 14, 2025 200,000 200,000 Other 11,662 11,662 Total indebtedness 1,836,662 1,336,662 Less: debt issuance costs (406) (593) Indebtedness, net 1,836,256 1,336,069 Less: current installments of long-term debt (225,000) — Long-term debt $ 1,611,256 $ 1,336,069 Credit Agreement On December 30, 2021, we amended and restated our revolving credit facility by entering into a Fourth Amended and Restated Credit Agreement (the "Credit Agreement") with a syndicate of lenders. The Credit Agreement is a five-year revolving credit facility expiring on December 30, 2026, with two one-year extension options that are subject to lender approval. The Credit Agreement includes: (a) a revolving credit loan facility of up to $1.225 billion at any time outstanding, and (b) a letter of credit facility of up to $200 million at any time outstanding (which is a sub-facility of the $1.225 billion revolving credit loan facility). The Credit Agreement also includes an accordion feature allowing an increase of the credit facility of up to an additional $500 million ($1.725 billion in the aggregate) at any time outstanding, subject to lender participation and the satisfaction of specified conditions. Prepayment of borrowings outstanding under the Credit Agreement is permitted at any time. Proceeds may be used for working capital and general corporate purposes, including but not limited to certain business acquisitions and purchases under our share repurchase programs. The Credit Agreement provides certain restrictions on our ability to borrow, incur liens, sell assets and pay dividends, and contains certain leverage and interest coverage covenants. Generally, interest on revolving credit loans is payable at a variable rate based on LIBOR, prime, or the U.S. federal funds rate, plus a spread that varies depending on leverage ratios maintained. Unused commitment, letter of credit, and other fees are also payable under the Credit Agreement. At December 31, 2021 and December 31, 2020, the interest rate on revolving credit loans outstanding was 0.90% and 0.95%, respectively, based on LIBOR plus the applicable spread. As of December 31, 2021, we had outstanding revolving credit loans and letters of credit of $600 million and $18 million, respectively; which reduced our available borrowing capacity to $607 million under the Credit Agreement. Interest Rate Swap We are exposed to market risk from fluctuations in the variable interest rates on outstanding indebtedness under our Credit Agreement. In order to manage this exposure, we have entered into an interest rate swap agreement, with an initial notional amount of $600 million, to hedge the variability of cash flows associated with such interest obligations through May 2024. The interest rate swap has an effective start date of May 13, 2019, and is designated as a cash flow hedge, which effectively fixes the interest rate on the hedged indebtedness under our Credit Agreement at 3.06% through May 2024. At December 31, 2021 and December 31, 2020, this swap was in a net liability position with an aggregate fair value of $17 million and $37 million, respectively; which is presented in our consolidated balance sheets in "Other current liabilities". We classify fair value measurements of our interest rate swap as Level 2, as further described in Note (12). Our interest rate swap agreement is accounted for in accordance with ASC Topic 815, Derivatives and Hedging . Such agreement is designated as a cash flow hedge and considered to be highly effective under hedge accounting principles. Therefore, the swap agreement is recognized in our consolidated balance sheets as either an asset or liability, measured at fair value. Changes in the fair value of the swap agreement are initially recorded in accumulated other comprehensive loss, net and then subsequently recognized in our consolidated statements of operations in the periods in which earnings are affected by the hedged item. All cash flows associated with the swap agreement are classified as operating activities in our consolidated statements of cash flows . Series 2021 Senior Notes We entered into a Master Note Agreement on November 11, 2019, and subsequently amended on October 8, 2020 (collectively and as amended, the "2019 Shelf Agreement"), pursuant to which we may issue and sell up to an aggregate principal amount of $1.80 billion of unsecured senior promissory notes. In March 2021, we issued $500 million aggregate principal amount of unsecured senior notes (the "Series 2021 Senior Notes"), pursuant to the 2019 Shelf Agreement. The issuance consisted of $100 million of 2.00% Series 2021-A Notes due March 24, 2026 and $400 million of 2.59% Series 2021-B Notes due March 24, 2031. Interest on the Series 2021 Senior Notes is payable semiannually on each March 24 and September 24, commencing September 24, 2021, and the principal balance is due at maturity. The Company may prepay at any time all, or any part of, the outstanding principal amount of the Series 2021 Senior Notes, subject to the payment of a make-whole amount. 2020 Senior Notes In March 2020, we issued $300 million aggregate principal amount of 2.50% senior unsecured Series 2020-A notes (the "Series 2020-A Notes") due March 11, 2030, pursuant to the 2019 Shelf Agreement. Interest on the Series 2020-A Notes is payable semiannually on each March 11 and September 11, commencing September 11, 2020, and the principal balance is due at maturity. The Company may prepay at any time all, or any part of, the outstanding principal amount of the Series 2020-A Notes, subject to the payment of a make-whole amount. The Series 2021 Senior Notes and Series 2020-A Notes are subject to the terms of the 2019 Shelf Agreement, which contains customary events of default and covenants related to limitations on indebtedness and transactions with affiliates and the maintenance of certain financial ratios. As of the date of this filing, $1.00 billion remains available for sale under the 2019 Shelf Agreement, which is uncommitted and subject to participation by the purchasers. 2015 Senior Notes On December 4, 2014, we entered into a Master Note Purchase Agreement (the "Master Note Purchase Agreement") with the Purchasers listed therein, pursuant to which we may issue and sell up to an aggregate principal amount of $1.50 billion of unsecured senior promissory notes to those Purchasers electing to purchase. In January 2015, we issued $500 million aggregate principal amount of unsecured Senior Notes ("Senior Notes"), pursuant to the Master Note Purchase Agreement. The issuance consisted of $225 million of 3.18% Series 2015-A Notes due February 15, 2022, $200 million of 3.58% Series 2015-B Notes due February 14, 2025, and $75 million in floating rate Series 2015-C Notes due February 15, 2022. Interest is payable semiannually on February 15th and August 15th in each year, commencing on August 15, 2015 for the Series 2015-A Notes and Series 2015-B Notes. The Master Note Purchase Agreement contains certain leverage and interest coverage ratio covenants and provides certain restrictions on our ability to borrow, incur liens, sell assets, and other customary terms. Proceeds from the Senior Notes are available for general corporate purposes. As of the date of this filing, the remaining $1.00 billion available for sale is uncommitted and subject to participation by the Purchasers under the Master Note Purchase Agreement. On February 15, 2022, we repaid our $225 million of Series 2015-A Notes due February 15, 2022. In March 2018, we repaid our $75 million floating rate Series 2015-C Notes due February 15, 2022. Other Other indebtedness includes estimated amounts payable through September 1, 2025, under an agreement entered into in September 2015. Covenant Compliance As of December 31, 2021, we were in compliance with all debt covenants. Maturities Maturities of indebtedness outstanding at the end of 2021 are as follows: (In thousands) Credit Agreement Loans Senior Notes Other Total 2022 $ — $ 225,000 $ — $ 225,000 2023 — — — — 2024 — — — — 2025 — 200,000 11,662 211,662 2026 600,000 100,000 — 700,000 2027 and thereafter — 700,000 — 700,000 Total $ 600,000 $ 1,225,000 $ 11,662 $ 1,836,662 |
Fair Value Measurements
Fair Value Measurements | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements We determine fair value measurements used in our consolidated financial statements based upon the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: • Level 1 – Valuations based on quoted prices in active markets for identical assets or liabilities that the entity has the ability to access. • Level 2 – Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. • Level 3 – Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The following table details our investments in available-for-sale debt securities measured and recorded at fair value on a recurring basis at the end of 2021: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 149,429 $ — $ — Time deposits Cash equivalents — 35,342 — Commercial paper Cash equivalents — 77,850 — Government and corporate bonds Cash equivalents — 5,000 — Time deposits Short-term investments — 25,598 — Commercial paper Short-term investments — 56,986 — Government and corporate bonds Short-term investments — 170,038 — Government and corporate bonds Long-term investments — 31,018 — The following table details our investments in available-for-sale debt securities measured and recorded at fair value on a recurring basis at the end of 2020: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 40,027 $ — $ — Time deposits Cash equivalents — 36,756 — Commercial paper Cash equivalents — 61,000 — Time deposits Short-term investments — 28,302 — Commercial paper Short-term investments — 263,993 — Government and corporate bonds Short-term investments — 150,178 — Government and corporate bonds Long-term investments — 137,078 — Our investments in equity securities with readily determinable fair values accounted for in accordance with ASC 321 were measured and recorded at fair value on a recurring basis using a Level 2 valuation. The fair value of such arrangements was based on quoted prices in active markets, reduced by a percentage reflecting a discount for lack of marketability. Our interest rate swap agreement is measured and recorded at fair value on a recurring basis using a Level 2 valuation. The fair value of such agreement is based on the market standard methodology of netting the discounted expected future variable cash receipts and the discounted future fixed cash payments. The variable cash receipts are based on an expectation of future interest rates derived from observed market interest rate forward curves. Since these inputs are observable in active markets over the terms that the instrument is held, the derivative is classified as Level 2 in the hierarchy. We estimate the fair value of our long-term, fixed rate debt using a Level 3 discounted cash flow analysis based on current borrowing rates for debt with similar maturities. We estimate the fair value of our long-term, variable rate debt using a Level 3 discounted cash flow analysis based on LIBOR rate forward curves. The fair value of our long-term debt, including current maturities, at the end of 2021 and 2020 was approximately $1.87 billion and $1.36 billion, respectively. The carrying amount of such debt at the end of 2021 and 2020 was $1.83 billion and $1.33 billion, respectively. |
Contingencies
Contingencies | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Contingencies Disclosure [Text Block] | Contingencies We accrue estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450, Contingencies ("ASC 450"). No less than quarterly, and as facts and circumstances change, we review the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. Should any one or a combination of more than one of these proceedings be successful, or should we determine to settle any one or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction or be forced to change the manner in which we operate our business, which could have a material adverse impact on our business, results of operations, cash flows or financial condition. On May 16, 2019, Steward Health Care System LLC ("Steward") filed a lawsuit in the Chancery Court for Davidson County, Tennessee against the Company. The Company believes Steward's allegations arise out of Steward's disinterest in following the contract between the Company and Steward's predecessor for clinical and financial software and services after Steward closed on its acquisition of the predecessor. The Company has filed a counterclaim against Steward seeking recovery of more than $42 million in unpaid invoices owed to the Company. The Company believes the dispute is in the ordinary course of business and the damages Steward asserts lack both factual and causal support. Steward has recently asserted that its damages are $300 million and advised the Company that it will seek to treble the damages. We have not concluded that a material loss related to the Steward allegations is probable, nor have we accrued a liability related to these claims. Although we believe a loss could be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss with respect to the potential damages given that the dispute is in the discovery process. We will continue to vigorously defend against these claims, and we continue to believe that we have valid grounds for recovery of the disputed client receivables. However, there can be no assurances as to the outcome of the dispute. On March 22, 2021, Astria Health ("Astria") filed an adversary proceeding in the United States Bankruptcy Court, Eastern District of Washington against the Company. Astria's allegations largely arise out of the Company's provision of revenue cycle services in 2018 and 2019. The Company believes the dispute is in the ordinary course of business and the factual allegations and the damages asserted lack both factual and causal support. Astria has recently claimed damages of $96 million. We have not concluded that a material loss related to the Astria allegations is probable, nor have we accrued a liability related to these claims beyond reserving certain bankruptcy-related outstanding invoices. Although we believe a loss could be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss with respect to the potential damages given that expert discovery is not yet complete. We will continue to vigorously defend against this claim. However, there can be no assurances as to the outcome of the dispute. The terms of our agreements with our clients generally provide for limited indemnification of such clients against losses, expenses and liabilities arising from third party or other claims based on, among other things, alleged infringement by our solutions of an intellectual property right of third parti es or damages caused by data privacy breaches or system interruptions. The terms of such indemnification often limit the scope of and remedies for such indemnification obligations and generally include, as applicable, a right to replace or modify an infringing solution. For several reasons, including the lack of a sufficient number of prior indemnification claims relating to intellectual property infringement, data privacy breaches or system interruptions, the inherent uncertainty stemming from such claims, and the lack of a monetary liability limit for such claims under the terms of the corresponding agreements with our clients, we cannot determine the maximum amount of potential future payments, if any, related to such indemnification provisions. In addition to commitments and obligations in the ordinary course of business, we are involved in various other legal proceedings and claims that arise in the ordinary course of business, including for example, employment and client disputes and litigation alleging solution and implementation defects, personal injury, intellectual property infringement, violations of law, breaches of contract and warranties, and compliance audits by various government agencies. Many of these proceedings are at preliminary stages and many seek an indeterminate amount of damages. At this time, we do not believe the range of potential losses under any claims to be material to our consolidated financial statements. |
Other Income
Other Income | 12 Months Ended |
Dec. 31, 2021 | |
Nonoperating Income (Expense) [Abstract] | |
Other Income | Other Income (Loss) A summary of non-operating income and expense is as follows: For the Years Ended (In thousands) 2021 2020 2019 Interest income $ 25,975 $ 28,901 $ 38,227 Interest expense (43,474) (29,080) (14,469) Gain on sale of equity investment — 75,834 15,509 Unrealized gain on equity investment — — 14,112 Other 8,683 1,251 464 Other income (loss), net $ (8,816) $ 76,906 $ 53,843 |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes Income tax expense (benefit) for 2021, 2020 and 2019 consists of the following: For the Years Ended (In thousands) 2021 2020 2019 Current: Federal $ 95,526 $ 131,741 $ 45,575 State 20,968 30,565 13,429 Foreign 20,019 47,577 14,929 Total current expense 136,513 209,883 73,933 Deferred: Federal (2,646) (4,469) 30,353 State 7,568 (96) 11,747 Foreign 2,429 6,067 9,025 Total deferred expense 7,351 1,502 51,125 Total income tax expense $ 143,864 $ 211,385 $ 125,058 Temporary differences between the financial statement carrying amounts and tax basis of assets and liabilities that give rise to significant portions of deferred income taxes at the end of 2021 and 2020 relate to the following: (In thousands) 2021 2020 Deferred tax assets: Accrued expenses $ 56,913 $ 63,080 Tax credits and separate return net operating losses 12,939 17,976 Contract and service revenues and costs 28,001 9,383 Share-based compensation 30,216 49,650 Lease liability 21,548 23,928 Other 15,070 17,554 Gross deferred tax assets 164,687 181,571 Less: Valuation Allowance (9,575) (3,384) Total deferred tax assets 155,112 178,187 Deferred tax liabilities: Software development costs (265,384) (270,041) Property and equipment (204,203) (204,568) Prepaid expenses (39,499) (37,547) Lease right-of-use assets (17,900) (20,639) Other (11,253) (9,260) Total deferred tax liabilities (538,239) (542,055) Net deferred tax liability $ (383,127) $ (363,868) At the end of 2021, we had net operating loss carry-forwards from foreign jurisdictions of $19 million that are available to offset future taxable income with no expiration. In addition, we had a state income tax credit carry-forward of $8 million available to offset income tax liabilities through December 31, 2030. During 2020, we recorded a valuation allowance of $3 million against the net operating loss carry-forward in a foreign jurisdiction due to a change in circumstances. During 2021, we recorded a valuation allowance of $6 million against the state income tax credit carry-forward due to a change in circumstances. At the end of 2021, we had not provided tax on the cumulative undistributed earnings of certain foreign subsidiaries of approximately $115 million, because it is our intention to reinvest these earnings indefinitely. The unrecognized deferred tax liability relating to these earnings is approximately $6 million. The effective income tax rates for 2021, 2020, and 2019 were 21%, 21%, and 19%, respectively. A reconciliation of the effective income tax rates to the U.S. federal statutory rate of 21% is follows: For the Years Ended (In thousands) 2021 2020 2019 Tax expense at statutory rates $ 146,887 $ 208,209 $ 137,447 State income tax, net of federal benefit 15,938 24,234 18,561 Tax credits (19,739) (21,254) (22,750) Foreign rate differential (8,940) 1,973 (6,328) Share-based compensation 7,351 (1,303) (8,090) Permanent differences 1,053 (6,534) 3,278 Other, net 1,314 6,060 2,940 Total income tax expense $ 143,864 $ 211,385 $ 125,058 A reconciliation of the beginning and ending amount of unrecognized tax benefit is presented below: (In thousands) 2021 2020 2019 Unrecognized tax benefit - beginning balance $ 22,204 $ 19,125 $ 18,688 Gross decreases - tax positions in prior periods (7,252) (3,964) (2,383) Gross increases - tax positions in prior periods 8,235 312 1,220 Gross increases - tax positions in current year 6,479 6,595 1,607 Gross increases - acquisition of businesses 5,112 — — Currency translation (439) 136 (7) Unrecognized tax benefit - ending balance $ 34,339 $ 22,204 $ 19,125 If recognized, $29 million of the unrecognized tax benefit will favorably impact our effective tax rate. It is reasonably possible that our unrecognized tax benefits may decrease by up to $12 million within the next twelve months. Our federal returns have been examined by the Internal Revenue Service through 2016. Our federal returns are open for examination for 2017 and thereafter. We have various state and foreign returns under examination. The ending amounts of accrued interest and penalties related to unrecognized tax benefits were $6 million in 2021 and $5 million in 2020. We classify interest and penalties as income tax expense in our consolidated statement of operations, and our income tax expense for 2021, 2020, and 2019 each included $1 million of interest and penalties. The foreign portion of our earnings before income taxes was $136 million, $208 million, and $109 million in 2021, 2020, and 2019 respectively, and the remaining portion was domestic. |
Earnings Per Share
Earnings Per Share | 12 Months Ended |
Dec. 31, 2021 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Earnings Per Share A reconciliation of the numerators and the denominators of the basic and diluted per share computations are as follows: 2021 2020 2019 Earnings Shares Per-Share Earnings Shares Per-Share Earnings Shares Per-Share (In thousands, except per share data) (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount Basic earnings per share: Income available to common shareholders $ 555,596 298,725 $ 1.86 $ 780,088 306,669 $ 2.54 $ 529,454 318,229 $ 1.66 Effect of dilutive securities: Stock options, non-vested shares and share units — 2,548 — 2,467 — 3,006 Diluted earnings per share: Income available to common shareholders including assumed conversions $ 555,596 301,273 $ 1.84 $ 780,088 309,136 $ 2.52 $ 529,454 321,235 $ 1.65 Options to purchase 0.4 million, 4.1 million and 9.6 million shares of common stock at per share prices ranging from $52.32 to $76.49, $52.32 to $76.49 and $52.32 to $75.83, were outstanding at the end of 2021, 2020 and 2019, respectively, but were not included in the computation of diluted earnings per share because they were anti-dilutive. |
Share-Based Compensation
Share-Based Compensation | 12 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Share-Based Compensation and Equity | Share-Based Compensation and Equity Stock Option and Equity Plans At the end of 2021, we had two fixed stock option and equity plans in effect for associates and directors. This includes one plan from which we could issue grants, the Cerner Corporation 2011 Omnibus Equity Incentive Plan (the "Omnibus Plan"); and one plan from which no new grants are permitted, but some awards remain outstanding (Plan E). Awards under the Omnibus Plan may consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, performance units, performance grants and bonus shares. At the end of 2021, 12.5 million shares remain available for awards. Stock options granted under the Omnibus Plan are exercisable at a price not less than fair market value on the date of grant. Stock options under the Omnibus Plan typically vest over a period of 4 or 5 years and are exercisable for periods of up to 10 years. Stock Options The fair market value of each stock option award granted in 2020 and 2019 was estimated on the date of grant using the Black-Scholes-Merton ("BSM") pricing model. The pricing model requires the use of the following estimates and assumptions: • Expected volatilities under the BSM model are based on an equal weighting of implied volatilities from traded options on our common shares and historical volatility. • The expected term of stock options granted is the period of time for which an option is expected to be outstanding beginning on the grant date. Our calculation of expected term takes into account the contractual term of the option, as well as the effects of employees' historical exercise patterns; groups of associates (executives and non-executives) that have similar historical behavior are considered separately for valuation purposes. • The risk-free rate is based on the zero-coupon U.S. Treasury bond with a term consistent with the expected term of the awards. The weighted-average assumptions used to estimate the fair market value of stock options were as follows: For the Years Ended 2020 2019 Expected volatility (%) 24.5 % 25.0 % Expected dividend rate (%) 1 % 1 % Expected term (yrs) 6 7 Risk-free rate (%) 1.1 % 2.4 % Stock option activity for 2021 was as follows: (In thousands, except per share and term data) Number of Weighted- Aggregate Weighted-Average Remaining Contractual Outstanding at beginning of year 10,204 $ 58.59 Granted — — Exercised (5,276) 57.75 Forfeited and expired (258) 57.32 Outstanding at end of year 4,670 59.61 $ 155,331 4.64 Exercisable at end of year 3,365 $ 58.85 $ 114,503 4.02 For the Years Ended (In thousands, except for grant date fair values) 2021 2020 2019 Weighted-average grant date fair values $ — $ 16.64 $ 17.51 Total intrinsic value of options exercised $ 110,916 $ 115,607 $ 155,202 Cash received from exercise of stock options 304,078 253,605 258,036 Tax benefit realized upon exercise of stock options 24,791 27,103 36,629 At the end of 2021, there was $14 million of total unrecognized compensation cost related to stock options granted under all plans. That cost is expected to be recognized over a weighted-average period of 1.20 years. Non-vested Shares and Share Units Non-vested shares and share units are valued at fair market value on the date of grant and will vest provided the recipient, if a member of the Board of Directors, has continuously served on the Board of Directors through such vesting date or, in the case of an associate, provided that service and/or performance measures are attained. The expense associated with these grants is recognized over the period from the date of grant to the vesting date. Non-vested share and share unit activity for 2021 was as follows: (In thousands, except per share data) Number of Shares Weighted-Average Outstanding at beginning of year 4,131 $ 68.05 Granted 2,872 76.01 Vested (2,681) 68.24 Forfeited (678) 72.53 Outstanding at end of year 3,644 $ 73.35 For the Years Ended (In thousands, except for grant date fair values) 2021 2020 2019 Weighted average grant date fair values for shares granted during the year $ 76.01 $ 70.12 $ 66.49 Total fair value of shares vested during the year $ 202,543 $ 70,355 $ 30,558 At the end of 2021, there was $195 million of total unrecognized compensation cost related to non-vested share and share unit awards granted under all plans. That cost is expected to be recognized over a weighted-average period of 1.99 years. Associate Stock Purchase Plan We maintain an associate stock purchase plan ("ASPP"), which qualifies under Section 423 of the Internal Revenue Code. Generally, the ASPP provides our U.S. based associates the opportunity to purchase shares of our common stock at a 15% discount. Purchases of shares are made on the open market and subsequently reissued to participants of the ASPP. The difference between the open market purchase price and the cost to the participants is recognized as compensation expense, as such difference is paid by Cerner, in cash. Share-Based Compensation Cost Our stock option and non-vested share and share unit awards qualify for equity classification. The costs of our ASPP, along with participant contributions, are recorded as a liability until open market purchases are completed. The amounts recognized in the consolidated statements of operations with respect to stock options, non-vested shares and share units and ASPP are as follows: For the Years Ended (In thousands) 2021 2020 2019 Stock option and non-vested share and share unit compensation expense $ 195,654 $ 153,449 $ 103,641 Associate stock purchase plan expense 5,786 5,478 6,053 Amounts capitalized in software development costs, net of amortization (4,199) (4,867) (410) Amounts charged against earnings, before income tax benefit $ 197,241 $ 154,060 $ 109,284 Amount of related income tax benefit recognized in earnings $ 38,623 $ 30,775 $ 20,967 Preferred Stock At the end of 2021 and 2020, we had 1.0 million shares of authorized but unissued preferred stock, $0.01 par value. Treasury Stock Under one of our share repurchase programs, which was initially approved by our Board of Directors on May 23, 2017, and most recently amended on December 12, 2019 (the "2017 Share Repurchase Program"), the Company was authorized to repurchase up to $3.70 billion of shares of our common stock, excluding transaction costs. The repurchases were to be effectuated in the open market, by block purchase, in privately negotiated transactions, or through other transactions managed by broker-dealers, or any combination thereof. This program was completed in the third quarter of 2021. On April 23, 2021, our Board of Directors approved a new share repurchase program (the "2021 Share Repurchase Program"), which authorizes the Company to repurchase up to $3.75 billion in the aggregate of shares of our common stock, excluding transaction costs. The 2021 Share Repurchase Program was incremental to our 2017 Share Repurchase Program. The repurchases are to be effectuated in the open market, by block purchase, in privately negotiated transactions, or through other transactions managed by broker-dealers, or any combination thereof. The 2021 Share Repurchase Program will expire on December 31, 2023. During 2021, 2020, and 2019, we repurchased 20.0 million, 10.6 million, and 18.8 million shares for total consideration of $1.50 billion, $757 million, and $1.30 billion, respectively, under our share repurchase programs. The shares were recorded as treasury stock and accounted for under the cost method. No repurchased shares have been retired. As of December 31, 2021, $3.18 billion remains available for repurchase under the 2021 Share Repurchase Program. Dividends Cash dividend activity in 2021, 2020, and 2019 was as follows: Date Declared Date of Record Payment Date Amount per Share May 29, 2019 June 18, 2019 July 26, 2019 $0.18 September 10, 2019 September 25, 2019 October 9, 2019 $0.18 December 12, 2019 December 27, 2019 January 9, 2020 $0.18 March 19, 2020 April 3, 2020 April 17, 2020 $0.18 May 21, 2020 June 5, 2020 July 17, 2020 $0.18 September 10, 2020 September 25, 2020 October 13, 2020 $0.18 December 10, 2020 December 28, 2020 January 12, 2021 $0.22 March 25, 2021 April 6, 2021 April 20, 2021 $0.22 May 19, 2021 June 28, 2021 July 13, 2021 $0.22 September 9, 2021 September 27, 2021 October 12, 2021 $0.22 December 9, 2021 December 27, 2021 January 11, 2022 $0.27 In connection with the declaration of such dividends, our non-vested shares and share units are entitled to dividend equivalents, which will be payable to the holder subject to, and upon vesting of, the underlying awards. Our outstanding stock options are not entitled to dividend or dividend equivalents. At December 31, 2021 and December 31, 2020, our consolidated balance sheets included liabilities for dividends payable of $81 million and $69 million, respectively, which are included in "Other current liabilities". Accumulated Other Comprehensive Loss, Net (AOCI) The components of AOCI, net of tax, were as follows: Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 29, 2018 $ (102,939) $ — $ (613) $ (103,552) Other comprehensive income (loss) before reclassifications (3,408) (13,078) 901 (15,585) Amounts reclassified from AOCI — 500 (23) 477 Balance at December 28, 2019 (106,347) (12,578) 265 (118,660) Other comprehensive income (loss) before reclassifications 12,897 (23,687) 194 (10,596) Amounts reclassified from AOCI — 8,477 (25) 8,452 Balance at December 31, 2020 (93,450) (27,788) 434 (120,804) Other comprehensive income (loss) before reclassifications (21,180) 4,241 (440) (17,379) Amounts reclassified from AOCI — 10,586 39 10,625 Balance at December 31, 2021 $ (114,630) $ (12,961) $ 33 $ (127,558) The effects on net earnings of amounts reclassified from AOCI were as follows: (In thousands) Years Ended AOCI Component Location 2021 2020 2019 Unrealized loss on cash flow hedge Other income, net $ (13,150) $ (10,622) $ (624) Income taxes 2,564 2,145 124 Net of tax (10,586) (8,477) (500) Unrealized holding gain (loss) on available-for-sale investments Other income, net (48) 31 29 Income taxes 9 (6) (6) Net of tax (39) 25 23 Total amount reclassified, net of tax $ (10,625) $ (8,452) $ (477) |
Foundations Retirement Plan
Foundations Retirement Plan | 12 Months Ended |
Dec. 31, 2021 | |
Retirement Benefits [Abstract] | |
Pension and Other Postretirement Benefits Disclosure [Text Block] | We maintain certain defined contribution retirement plans (the "Plans"), which qualify under Section 401(k) of the Internal Revenue Code. Generally, the Plans allow our U.S. associates to make salary contributions to the Plans, subject to annual limitations determined by the Internal Revenue Service. The Plans provide for certain discretionary matches on behalf of the participants for which we recognized expenses of $38 million, $61 million and $59 million in 2021, 2020 and 2019, respectively. |
Commitments
Commitments | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | We have purchase commitments with various vendors, under agreements through 2030. Aggregate future payments under these commitments are as follows: (In thousands) Purchase Obligations 2022 $ 54,308 2023 54,308 2024 40,933 2025 45,819 2026 52,054 2027 and thereafter 368,882 $ 616,304 |
Segment Reporting
Segment Reporting | 12 Months Ended |
Dec. 31, 2021 | |
Segment Reporting [Abstract] | |
Segment Reporting | Segment Reporting We have two operating segments, Domestic and International. Revenues are derived primarily from the sale of clinical, financial and administrative information solutions and services. The cost of revenues includes the cost of third-party consulting services, computer hardware, devices and sublicensed software purchased from manufacturers for delivery to clients. It also includes the cost of hardware maintenance and sublicensed software support subcontracted to the manufacturers. Operating expenses incurred by the geographic business segments consist of sales and client service expenses including salaries of sales and client service personnel, expenses associated with our managed services business, marketing expenses, communications expenses and unreimbursed travel expenses. "Other" includes expenses that have not been allocated to the operating segments, such as software development, general and administrative expenses, certain organizational restructuring and other expense, share-based compensation expense, and certain amortization and depreciation. "Other" also includes gains or losses recognized on the divestiture of businesses. Performance of the segments is assessed at the operating earnings level by our chief operating decision maker, who is our Chief Executive Officer. Items such as interest, income taxes, capital expenditures and total assets are managed at the consolidated level and thus are not included in our operating segment disclosures. Accounting policies for each of the reportable segments are the same as those used on a consolidated basis. The following table presents a summary of our operating segments and other expense for 2021, 2020 and 2019: (In thousands) Domestic International Other Total 2021 Revenues $ 5,044,629 $ 720,195 $ — $ 5,764,824 Costs of revenue 887,343 113,674 — 1,001,017 Operating expenses 2,358,897 277,308 1,419,326 4,055,531 Total costs and expenses 3,246,240 390,982 1,419,326 5,056,548 Operating earnings (loss) $ 1,798,389 $ 329,213 $ (1,419,326) $ 708,276 (In thousands) Domestic International Other Total 2020 Revenues $ 4,879,769 $ 626,019 $ — $ 5,505,788 Costs of revenue 854,574 78,367 — 932,941 Operating expenses 2,339,624 242,991 1,296,188 3,878,803 Total costs and expenses 3,194,198 321,358 1,296,188 4,811,744 Gain on sale of businesses — — 220,523 220,523 Operating earnings (loss) $ 1,685,571 $ 304,661 $ (1,075,665) $ 914,567 (In thousands) Domestic International Other Total 2019 Revenues $ 5,038,127 $ 654,471 $ — $ 5,692,598 Costs of revenue 967,035 104,006 — 1,071,041 Operating expenses 2,398,422 276,914 1,345,552 4,020,888 Total costs and expenses 3,365,457 380,920 1,345,552 5,091,929 Operating earnings (loss) $ 1,672,670 $ 273,551 $ (1,345,552) $ 600,669 |
Basis of Presentation, Nature_2
Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation | The consolidated financial statements were prepared using accounting principles generally accepted in the United States of America ("GAAP"). |
Use of Estimates | These principles require us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. |
Nature of Operations | Nature of Operations We design, develop, market, install, host and support healthcare information technology, healthcare devices, hardware and content solutions for healthcare organizations and consumers. We also provide a wide range of value-added services, including implementation and training, remote hosting, operational management services, revenue cycle services, support and maintenance, healthcare data analysis, clinical process optimization, transaction processing, employer health centers, and data-driven services that help life sciences companies with the discovery, development and deployment of therapies. |
Fiscal Period | Prior to fiscal year 2020, our fiscal year ended on the Saturday closest to December 31. Fiscal year 2019 consisted of 364 days and ended on December 28, 2019. |
Cash Equivalents | Cash Equivalents - Cash equivalents consist of short-term debt securities with original maturities of less than 90 days. |
Investments | Investments in Debt Securities – We account for our investments in debt securities as available-for-sale investments in accordance with Accounting Standards Codification Topic ("ASC") 320, Investments-Debt Securities . Short-term available-for-sale investments are primarily invested in time deposits, commercial paper, government and corporate bonds, with maturities of less than one year. Long-term available-for-sale investments are primarily invested in government and corporate bonds with maturities of less than two years. Available-for-sale investments are recorded at fair value with the unrealized gains and losses reflected in accumulated other comprehensive loss until realized. Realized gains and losses from the sale of available-for-sale investments, if any, are determined on a specific identification basis. Generally, premiums are amortized and discounts are accreted over the life of the security as adjustments to interest income for our investments. For investments in callable debt securities, any premiums are amortized to the earliest call date. Interest income is recognized when earned. Refer to Note (4) and Note (12) for further description of these assets and their fair value. (c) Investments in Equity Securities - We account for our investments in equity securities that give us the ability to exercise significant influence over the operating and financial policies of an investee under the equity method in accordance with ASC 323, Investments-Equity Method and Joint Ventures . Under the equity method, we recognize our share of the earnings or losses of an investee, generally on a three-month lag. Such share of the investee's earnings or losses are presented in "Other income (loss), net" in our consolidated statements of operations. We account for our investments in equity securities that do not qualify for equity method accounting in accordance with ASC 321, Investments-Equity Securities ("ASC 321"). We measure these investments at fair value with changes in fair value recognized in "Other income (loss), net" in our consolidated statements of operations for such investments with readily determinable fair values. For these investments that do not have readily determinable fair values, we measure such investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. |
Concentrations | Concentrations - The majority of our cash and cash equivalents are held at three major financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally these deposits may be redeemed upon demand. |
Inventory | Inventory - Inventory consists primarily of computer hardware and sublicensed software, held for resale. Inventory is recorded at the lower of cost (first-in, first-out) or net realizable value. |
Property and Equipment | Property and Equipment - We account for property and equipment in accordance with ASC 360, Property, Plant, and Equipment . Property, equipment and leasehold improvements are stated at cost. Depreciation of property and equipment is computed using the straight-line method over periods of one to 50 years. Amortization of leasehold improvements is computed using a straight-line method over the shorter of the lease terms or the useful lives, which range from periods of one to 15 years. |
Goodwill | Goodwill - We account for goodwill under the provisions of ASC 350, Intangibles – Goodwill and Other . Goodwill is not amortized but is evaluated for impairment annually or whenever there is an impairment indicator. All goodwill is assigned to a reporting unit, where it is subject to an annual impairment assessment. Based on these evaluations, there was no impairment of goodwill in 2021, 2020 or 2019. Refer to Note (10) for more information on goodwill and other intangible assets. |
Intangible Assets | Intangible Assets - We account for intangible assets in accordance with ASC 350, Intangibles – Goodwill and Other . Amortization of finite-lived intangible assets is computed using the straight-line method over periods of three to 30 years. |
Income Taxes | Income Taxes - Income taxes are accounted for in accordance with ASC 740, Income Taxes . Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Refer to Note (14) for additional information regarding income taxes. |
Earnings per Common Share | Earnings per Common Share - Basic earnings per share ("EPS") excludes dilution and is computed, in accordance with ASC 260, Earnings Per Share , by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in our earnings. Refer to Note (15) for additional details of our earnings per share computations. |
Accounting for Share-based Payments | Accounting for Share-based Payments - We recognize all share-based payments to associates, directors and consultants, including grants of stock options, restricted stock, restricted stock units and performance shares, in the financial statements as compensation cost based on their fair value on the date of grant, in accordance with ASC 718, Compensation-Stock Compensation . This compensation cost is recognized over the vesting period on a straight-line basis for the fair value of awards that actually vest. Refer to Note (16) for a detailed discussion of share-based payments. |
Postemployment Benefit Plans | Voluntary Separation Benefits - We account for voluntary separation benefits in accordance with the provisions of ASC 712, Compensation-Nonretirement Postemployment Benefits . Voluntary separation benefits are recorded to expense when an associate irrevocably accepts the offer and the amount of the termination liability is reasonably estimable. |
Costs Associated with Exit or Disposal Activities or Restructurings | Exit or Disposal Cost Obligations - We account for involuntary employee separation benefits pursuant to one-time benefit arrangements and contract termination costs in accordance with ASC 420, Exit or Disposal Cost Obligations . |
Foreign Currency | Foreign Currency - In accordance with ASC 830, Foreign Currency Matters , assets and liabilities of non-U.S. subsidiaries whose functional currency is the local currency are translated into U.S. dollars at exchange rates prevailing at the balance sheet date. Revenues and expenses are translated at average exchange rates during the year. The net exchange differences resulting from these translations are reported in accumulated other comprehensive loss. Gains and losses resulting from foreign currency transactions are included in the consolidated statements of operations. |
Receivables Trade and Other Acc
Receivables Trade and Other Accounts Receivable (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Receivables [Abstract] | |
Accounts Receivable [Policy Text Block] | Client receivables primarily represent recorded revenues that have either been billed, or for which we have an unconditional right to invoice and receive payment in the future. We periodically provide long-term financing options to creditworthy clients through extended payment terms. Generally, these extended payment terms provide for date-based payments over a fixed period, not to exceed the term of the overall arrangement. Thus, our portfolio of client contracts contains a financing component, which is recognized over time as a component of "Other income (loss), net" in our consolidated statements of operations. We perform ongoing credit evaluations of our clients and generally do not require collateral from our clients. |
Software Development Costs (Pol
Software Development Costs (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Research and Development [Abstract] | |
Software Development Costs | Our software solutions are offered to our clients both through traditional licenses as well as software as a service delivery models. Development costs associated with the certain solutions offered exclusively through a software as a service model are accounted for in accordance with ASC 350-40, Internal-Use Software . All other client solution development costs, which represent a significant majority of development costs, are accounted for in accordance with ASC 985-20, Costs of Software to be Sold, Leased or Marketed . Under ASC 985-20, software development costs incurred in creating computer software solutions are expensed until technological feasibility has been established upon completion of a detailed program design. Thereafter, all software development costs incurred through the software's general release date are capitalized and subsequently recorded at the lower of amortized cost or net realizable value. Capitalized costs are amortized based on current and expected future revenue for each software solution with minimum annual amortization equal to the straight-line amortization over the estimated economic life of the solution. We amortize capitalized costs over five years. Under ASC 350-40, software development costs related to preliminary project activities and post-implementation and maintenance activities are expensed as incurred. We capitalize direct costs related to application development activities that are probable to result in additional functionality. Capitalized costs are amortized on a straight-line basis over five years. We test for impairment whenever events or changes in circumstances that could impact recoverability occur. |
Business Acquisition (Policies)
Business Acquisition (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Business Combinations [Abstract] | |
Business Combinations Policy [Policy Text Block] | Our acquisition of Kantar Health was treated as a purchase in accordance with ASC 805, Business Combinations |
Debt (Policies)
Debt (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
Derivatives, Methods of Accounting, Hedging Derivatives [Policy Text Block] | Our interest rate swap agreement is accounted for in accordance with ASC Topic 815, Derivatives and Hedging . Such agreement is designated as a cash flow hedge and considered to be highly effective under hedge accounting principles. Therefore, the swap agreement is recognized in our consolidated balance sheets as either an asset or liability, measured at fair value. Changes in the fair value of the swap agreement are initially recorded in accumulated other comprehensive loss, net and then subsequently recognized in our consolidated statements of operations in the periods in which earnings are affected by the hedged item. All cash flows associated with the swap agreement are classified as operating activities in our consolidated statements of cash flows |
Fair Value Measurements Policie
Fair Value Measurements Policies (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments, Policy [Policy Text Block] | We determine fair value measurements used in our consolidated financial statements based upon the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3) |
Contingencies Details (Policies
Contingencies Details (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies, Policy [Policy Text Block] | We accrue estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450, Contingencies ("ASC 450"). No less than quarterly, and as facts and circumstances change, we review the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. Should any one or a combination of more than one of these proceedings be successful, or should we determine to settle any one or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction or be forced to change the manner in which we operate our business, which could have a material adverse impact on our business, results of operations, cash flows or financial condition. |
Revenue from Contract with Cu_2
Revenue from Contract with Customer (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Disaggregation of Revenue [Table Text Block] | Disaggregation of Revenue The following table presents revenues disaggregated by our business models: For the Years Ended 2021 2020 2019 (In thousands) Domestic International Total Domestic International Total Domestic International Total Licensed software $ 671,926 $ 53,730 $ 725,656 $ 604,707 $ 51,512 $ 656,219 $ 628,958 $ 51,627 $ 680,585 Technology resale 163,280 21,392 184,672 173,264 23,327 196,591 225,076 21,809 246,885 Subscriptions 365,936 16,922 382,858 354,023 24,185 378,208 333,298 25,417 358,715 Professional services 1,817,213 299,278 2,116,491 1,717,873 212,572 1,930,445 1,760,532 231,946 1,992,478 Managed services 1,143,188 145,265 1,288,453 1,120,939 124,488 1,245,427 1,098,695 115,205 1,213,900 Support and maintenance 849,428 183,479 1,032,907 881,778 189,001 1,070,779 904,204 200,434 1,104,638 Reimbursed travel 33,658 129 33,787 27,185 934 28,119 87,364 8,033 95,397 Total revenues $ 5,044,629 $ 720,195 $ 5,764,824 $ 4,879,769 $ 626,019 $ 5,505,788 $ 5,038,127 $ 654,471 $ 5,692,598 The following table presents our revenues disaggregated by timing of revenue recognition: For the Years Ended 2021 2020 2019 (In thousands) Domestic International Total Domestic International Total Domestic International Total Revenue recognized over time $ 4,736,395 $ 680,557 $ 5,416,952 $ 4,557,358 $ 585,316 $ 5,142,674 $ 4,565,172 $ 600,953 $ 5,166,125 Revenue recognized at a point in time 308,234 39,638 347,872 322,411 40,703 363,114 472,955 53,518 526,473 Total revenues $ 5,044,629 $ 720,195 $ 5,764,824 $ 4,879,769 $ 626,019 $ 5,505,788 $ 5,038,127 $ 654,471 $ 5,692,598 |
Receivables (Tables)
Receivables (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Receivables [Abstract] | |
Summary of Net Receivables | A summary of net receivables is as follows: (In thousands) 2021 2020 Client receivables $ 1,307,167 $ 1,322,278 Less: Provision for expected credit losses 145,806 153,566 Total receivables, net $ 1,161,361 $ 1,168,712 |
Accounts Receivable, Allowance for Credit Loss | A reconciliation of the beginning and ending amount of our provision for expected credit losses is as follows: (In thousands) Current Non-current Total Provision for expected credit losses - balance at December 29, 2018 $ 64,561 $ 63,849 $ 128,410 Additions charged to costs and expenses 57,167 — 57,167 Deductions, foreign currency and other (15,653) 1,490 (14,163) Provision for expected credit losses - balance at December 28, 2019 106,075 65,339 171,414 Cumulative effect of accounting change (ASU 2016-13) 4,606 — 4,606 Additions charged to costs and expenses 65,099 20,703 85,802 Deductions, foreign currency and other (22,214) (47,478) (69,692) Provision for expected credit losses - balance at December 31, 2020 153,566 38,564 192,130 Additions charged to costs and expenses 39,791 — 39,791 Reclassifications to non-current (26,480) 26,480 — Deductions, foreign currency and other (21,071) (3,938) (25,009) Provision for expected credit losses - balance at December 31, 2021 $ 145,806 $ 61,106 $ 206,912 |
Schedule Of New Accounting Pronouncements And Changes In Accounting Principles Text Block ASU 2016-13 | A summary of such cumulative effect adjustment is as follows: (In thousands) Increase/(Decrease) Receivables, net $ (4,606) Retained earnings (4,606) |
Investments Investments (Tables
Investments Investments (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Investments [Abstract] | |
Schedule of available-for-sale investments | Available-for-sale investments at the end of 2021 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 149,429 $ — $ — $ 149,429 Time deposits 35,342 — — 35,342 Commercial paper 77,850 — — 77,850 Government and corporate bonds 5,000 — — 5,000 Total cash equivalents 267,621 — — 267,621 Short-term investments: Time deposits 25,598 — — 25,598 Commercial paper 57,000 — (14) 56,986 Government and corporate bonds 170,123 18 (103) 170,038 Total short-term investments 252,721 18 (117) 252,622 Long-term investments: Government and corporate bonds 31,167 — (149) 31,018 Total available-for-sale investments $ 551,509 $ 18 $ (266) $ 551,261 Available-for-sale investments at the end of 2020 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 40,027 $ — $ — $ 40,027 Time deposits 36,756 — — 36,756 Commercial Paper 61,000 — — 61,000 Total cash equivalents 137,783 — — 137,783 Short-term investments: Time deposits 28,302 — — 28,302 Commercial Paper 264,000 12 (19) 263,993 Government and corporate bonds 149,975 247 (44) 150,178 Total short-term investments 442,277 259 (63) 442,473 Long-term investments: Government and corporate bonds 136,983 152 (57) 137,078 Total available-for-sale investments $ 717,043 $ 411 $ (120) $ 717,334 |
Property and Equipment (Tables)
Property and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment | A summary of property, equipment and leasehold improvements stated at cost, less accumulated depreciation and amortization, is as follows: (In thousands) Depreciable Lives (Yrs) 2021 2020 Held and used: Computer and communications equipment 1 — 5 $ 1,981,488 $ 1,939,517 Land, buildings and improvements 12 — 50 1,180,042 1,403,835 Leasehold improvements 1 — 15 202,283 208,496 Furniture and fixtures 5 — 12 116,236 146,351 Other equipment 3 — 20 20,444 1,025 3,500,493 3,699,224 Less accumulated depreciation and leasehold amortization 1,933,623 1,895,141 Property and equipment held and used 1,566,870 1,804,083 Assets held for sale 89,301 — Property and equipment, net $ 1,656,171 $ 1,804,083 |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Leases [Abstract] | |
Schedule of New Accounting Pronouncements and Changes in Accounting Principles | A summary of such cumulative effect adjustment is as follows: (In thousands) Increase / Right-of-use asset $ 129,652 Prepaid expenses and other 3,968 Other current liabilities 22,767 Other liabilities 110,853 |
Lessee, Operating Lease Amounts Included in Balance Sheet [Table Text Block] | The following table presents a summary of lease liability and right-of-use asset amounts included in our consolidated balance sheets at the end of 2021 and 2020, under operating lease arrangements where we are the lessee: (In thousands) Description Balance Sheet Classification 2021 2020 Right-of-use asset Right-of-use assets $ 82,940 $ 104,536 Lease liability - current Other current liabilities 27,694 29,913 Lease liability - non-current Other liabilities 67,160 90,106 |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Aggregate future payments under operating lease arrangements where we are the lessee (by fiscal year) are as follows: (In thousands) Operating Lease Obligations 2022 $ 27,694 2023 20,826 2024 13,824 2025 8,884 2026 5,978 2027 and thereafter 32,031 Aggregate future payments 109,237 Impact of discounting (14,383) Aggregate lease liability at December 31, 2021 $ 94,854 |
Software Development Costs (Tab
Software Development Costs (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Research and Development [Abstract] | |
Schedule of Software Development Costs, Net [Table Text Block] | A summary of software development costs, net is as follows: 2021 2020 (In thousands) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Software to be sold, leased or marketed $ 2,751,960 $ 1,985,051 $ 2,610,476 $ 1,788,019 Software delivered exclusively as a service 474,712 241,264 385,168 198,276 Total $ 3,226,672 $ 2,226,315 $ 2,995,644 $ 1,986,295 Software development costs, net $ 1,000,357 $ 1,009,349 |
Schedule of Capitalized Software, Future Amortization Expense [Table Text Block] | Estimated aggregate amortization expense for each of the next five years is as follows: (In thousands) 2022 $ 280,626 2023 247,172 2024 201,507 2025 146,610 2026 90,212 |
Schedule of Software Development Costs | Information regarding our software development costs is included in the following table: For the Years Ended (In thousands) 2021 2020 2019 Software development costs $ 828,502 $ 796,971 $ 783,593 Capitalized software development costs (308,026) (295,277) (273,871) Amortization of capitalized software development costs 261,798 247,313 227,414 Net realizable value charges 53,721 — — Total software development expense $ 835,995 $ 749,007 $ 737,136 |
Business Acquisition (Tables)
Business Acquisition (Tables) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Business Acquisition [Line Items] | |||
Schedule of Business Acquisitions, by Acquisition [Table Text Block] | The final allocation of purchase price was as follows: (In thousands) Allocation Amount Cash and cash equivalents $ 15,311 Receivables, net 32,616 Prepaid expenses and other 8,881 Property and equipment, net 1,198 Right-of-use assets 1,939 Goodwill 226,232 Intangible assets, net: Customer relationships 143,100 Existing technologies 39,700 Trade names 10,200 Other assets 428 Accounts payable (36,748) Deferred revenue (35,698) Accrued payroll and tax withholdings (11,172) Other current liabilities (3,189) Deferred income taxes (11,733) Other liabilities (10,250) Total purchase price $ 370,815 | The aggregate final allocation of purchase price for our 2020 acquisitions was as follows: (In thousands) Allocation Amount Receivables, net $ 2,313 Inventory 863 Prepaid expenses and other 331 Property and equipment, net 114 Right-of-use assets 683 Goodwill 33,709 Intangible assets, net 16,510 Other assets 179 Accounts payable (880) Deferred revenue (3,158) Accrued payroll and tax withholdings (501) Other current liabilities (713) Deferred income taxes (374) Total purchase price $ 49,076 | The final allocation of purchase price was as follows: (In thousands) Allocation Amount Cash and cash equivalents $ 471 Receivables, net 11,690 Prepaid expenses and other 911 Property and equipment, net 1,240 Right-of-use assets 8,448 Goodwill 37,815 Intangible assets, net 37,402 Accounts payable (5,244) Deferred revenue (157) Accrued payroll and tax withholdings (5,812) Other current liabilities (2,994) Other liabilities (8,016) Total purchase price $ 75,754 |
Gain on sale of businesses (Tab
Gain on sale of businesses (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Disposal Groups, Including Discontinued Operations | The following table presents a reconciliation of the sale price to the net gain recognized on the disposed business operations which is included in "Gain on sale of businesses" in our consolidated statements of operations: (In thousands) Sale price $ 230,316 Net assets/liabilities removed (7,934) Transaction expenses (5,583) Foreign currency 1,550 Gain on sale of businesses $ 218,349 The following table presents a reconciliation of the sale price to the cash proceeds received from CGM which are included in "Sale of businesses" in our consolidated statements of cash flows: (In thousands) Sale price $ 230,316 Receivable due from CGM (4,049) VAT and other transaction taxes, net (2,142) Foreign currency 356 Cash received from sale of businesses $ 224,481 Amounts included in our consolidated balance sheets related to the disposed business operations immediately prior to the sale on July 1, 2020 were as follows: (In thousands) Asset/(Liability) Receivables, net $ 8,646 Inventory 65 Prepaid expenses and other 5,993 Property and equipment, net 340 Right-of-use assets 554 Software development costs, net 5,532 Goodwill 7,692 Intangible assets, net 3,687 Accounts payable (2,763) Deferred revenue (16,756) Accrued payroll and tax withholdings (4,545) Other current liabilities (511) Net assets/(liabilities) $ 7,934 |
Goodwill and Other Intangible_2
Goodwill and Other Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Changes in Carrying Amounts of Goodwill | The changes in the carrying amounts of goodwill by segment were as follows: (In thousands) Domestic International Total Balance at the end of 2019 $ 819,735 $ 63,423 $ 883,158 Purchase price allocation adjustments for the AbleVets acquisition 744 — 744 Goodwill recorded in connection with 2020 business acquisitions 33,709 — 33,709 Goodwill reduction in connection with divestiture transactions — (7,692) (7,692) Foreign currency translation adjustment and other — 4,601 4,601 Balance at the end of 2020 854,188 60,332 914,520 Goodwill recorded in connection with the Kantar Health acquisition 119,709 106,523 226,232 Foreign currency translation adjustment and other — (9,631) (9,631) Balance at the end of 2021 $ 973,897 $ 157,224 $ 1,131,121 |
Schedule of Finite-Lived Intangible Assets | A summary of net intangible assets is as follows: 2021 2020 (In thousands) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Customer lists $ 636,410 $ 360,598 $ 494,615 $ 312,044 Purchased software 396,508 346,381 354,228 337,811 Internal use software 233,438 150,356 207,696 123,280 Trade names 52,883 33,719 42,951 28,961 Other 52,179 21,882 50,535 18,680 Total $ 1,371,418 $ 912,936 $ 1,150,025 $ 820,776 Intangible assets, net $ 458,482 $ 329,249 |
Schedule of Finite-Lived Intangible Asets, Future Amortization Expense | Estimated aggregate amortization expense for each of the next five years is as follows: (In thousands) 2022 $ 96,281 2023 86,863 2024 79,985 2025 38,916 2026 20,769 |
Indebtedness (Tables)
Indebtedness (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
Schedule of Indebtedness Outstanding | The following is a summary of indebtedness outstanding: (In thousands) 2021 2020 Credit agreement loans due December 30, 2026 $ 600,000 $ 600,000 Senior notes: Series 2021-A due March 24, 2026 100,000 — Series 2021-B due March 24, 2031 400,000 — Series 2020-A due March 11, 2030 300,000 300,000 Series 2015-A due February 15, 2022 225,000 225,000 Series 2015-B due February 14, 2025 200,000 200,000 Other 11,662 11,662 Total indebtedness 1,836,662 1,336,662 Less: debt issuance costs (406) (593) Indebtedness, net 1,836,256 1,336,069 Less: current installments of long-term debt (225,000) — Long-term debt $ 1,611,256 $ 1,336,069 |
Schedule of Minimum Annual Payments Under Capital Lease Obligation and Maturities of Indebtedness | Maturities of indebtedness outstanding at the end of 2021 are as follows: (In thousands) Credit Agreement Loans Senior Notes Other Total 2022 $ — $ 225,000 $ — $ 225,000 2023 — — — — 2024 — — — — 2025 — 200,000 11,662 211,662 2026 600,000 100,000 — 700,000 2027 and thereafter — 700,000 — 700,000 Total $ 600,000 $ 1,225,000 $ 11,662 $ 1,836,662 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | The following table details our investments in available-for-sale debt securities measured and recorded at fair value on a recurring basis at the end of 2021: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 149,429 $ — $ — Time deposits Cash equivalents — 35,342 — Commercial paper Cash equivalents — 77,850 — Government and corporate bonds Cash equivalents — 5,000 — Time deposits Short-term investments — 25,598 — Commercial paper Short-term investments — 56,986 — Government and corporate bonds Short-term investments — 170,038 — Government and corporate bonds Long-term investments — 31,018 — The following table details our investments in available-for-sale debt securities measured and recorded at fair value on a recurring basis at the end of 2020: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 40,027 $ — $ — Time deposits Cash equivalents — 36,756 — Commercial paper Cash equivalents — 61,000 — Time deposits Short-term investments — 28,302 — Commercial paper Short-term investments — 263,993 — Government and corporate bonds Short-term investments — 150,178 — Government and corporate bonds Long-term investments — 137,078 — |
Other Income (Tables)
Other Income (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Nonoperating Income (Expense) [Abstract] | |
Schedule of Other Nonoperating Income (Expense) [Table Text Block] | A summary of non-operating income and expense is as follows: For the Years Ended (In thousands) 2021 2020 2019 Interest income $ 25,975 $ 28,901 $ 38,227 Interest expense (43,474) (29,080) (14,469) Gain on sale of equity investment — 75,834 15,509 Unrealized gain on equity investment — — 14,112 Other 8,683 1,251 464 Other income (loss), net $ (8,816) $ 76,906 $ 53,843 |
Income Taxes Income Taxes (Tabl
Income Taxes Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Schedule of Components of Income Tax Expense (Benefit) | Income tax expense (benefit) for 2021, 2020 and 2019 consists of the following: For the Years Ended (In thousands) 2021 2020 2019 Current: Federal $ 95,526 $ 131,741 $ 45,575 State 20,968 30,565 13,429 Foreign 20,019 47,577 14,929 Total current expense 136,513 209,883 73,933 Deferred: Federal (2,646) (4,469) 30,353 State 7,568 (96) 11,747 Foreign 2,429 6,067 9,025 Total deferred expense 7,351 1,502 51,125 Total income tax expense $ 143,864 $ 211,385 $ 125,058 |
Schedule of Deferred Tax Assets and Liabilities | Temporary differences between the financial statement carrying amounts and tax basis of assets and liabilities that give rise to significant portions of deferred income taxes at the end of 2021 and 2020 relate to the following: (In thousands) 2021 2020 Deferred tax assets: Accrued expenses $ 56,913 $ 63,080 Tax credits and separate return net operating losses 12,939 17,976 Contract and service revenues and costs 28,001 9,383 Share-based compensation 30,216 49,650 Lease liability 21,548 23,928 Other 15,070 17,554 Gross deferred tax assets 164,687 181,571 Less: Valuation Allowance (9,575) (3,384) Total deferred tax assets 155,112 178,187 Deferred tax liabilities: Software development costs (265,384) (270,041) Property and equipment (204,203) (204,568) Prepaid expenses (39,499) (37,547) Lease right-of-use assets (17,900) (20,639) Other (11,253) (9,260) Total deferred tax liabilities (538,239) (542,055) Net deferred tax liability $ (383,127) $ (363,868) |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | The effective income tax rates for 2021, 2020, and 2019 were 21%, 21%, and 19%, respectively. A reconciliation of the effective income tax rates to the U.S. federal statutory rate of 21% is follows: For the Years Ended (In thousands) 2021 2020 2019 Tax expense at statutory rates $ 146,887 $ 208,209 $ 137,447 State income tax, net of federal benefit 15,938 24,234 18,561 Tax credits (19,739) (21,254) (22,750) Foreign rate differential (8,940) 1,973 (6,328) Share-based compensation 7,351 (1,303) (8,090) Permanent differences 1,053 (6,534) 3,278 Other, net 1,314 6,060 2,940 Total income tax expense $ 143,864 $ 211,385 $ 125,058 |
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] | A reconciliation of the beginning and ending amount of unrecognized tax benefit is presented below: (In thousands) 2021 2020 2019 Unrecognized tax benefit - beginning balance $ 22,204 $ 19,125 $ 18,688 Gross decreases - tax positions in prior periods (7,252) (3,964) (2,383) Gross increases - tax positions in prior periods 8,235 312 1,220 Gross increases - tax positions in current year 6,479 6,595 1,607 Gross increases - acquisition of businesses 5,112 — — Currency translation (439) 136 (7) Unrecognized tax benefit - ending balance $ 34,339 $ 22,204 $ 19,125 |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Earnings Per Share [Abstract] | |
Reconciliation Of The Numerators And The Denominators Of The Basic And Diluted Per Share | A reconciliation of the numerators and the denominators of the basic and diluted per share computations are as follows: 2021 2020 2019 Earnings Shares Per-Share Earnings Shares Per-Share Earnings Shares Per-Share (In thousands, except per share data) (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount Basic earnings per share: Income available to common shareholders $ 555,596 298,725 $ 1.86 $ 780,088 306,669 $ 2.54 $ 529,454 318,229 $ 1.66 Effect of dilutive securities: Stock options, non-vested shares and share units — 2,548 — 2,467 — 3,006 Diluted earnings per share: Income available to common shareholders including assumed conversions $ 555,596 301,273 $ 1.84 $ 780,088 309,136 $ 2.52 $ 529,454 321,235 $ 1.65 |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | The weighted-average assumptions used to estimate the fair market value of stock options were as follows: For the Years Ended 2020 2019 Expected volatility (%) 24.5 % 25.0 % Expected dividend rate (%) 1 % 1 % Expected term (yrs) 6 7 Risk-free rate (%) 1.1 % 2.4 % |
Schedule Of Stock Options Activity | Stock option activity for 2021 was as follows: (In thousands, except per share and term data) Number of Weighted- Aggregate Weighted-Average Remaining Contractual Outstanding at beginning of year 10,204 $ 58.59 Granted — — Exercised (5,276) 57.75 Forfeited and expired (258) 57.32 Outstanding at end of year 4,670 59.61 $ 155,331 4.64 Exercisable at end of year 3,365 $ 58.85 $ 114,503 4.02 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] | For the Years Ended (In thousands, except for grant date fair values) 2021 2020 2019 Weighted-average grant date fair values $ — $ 16.64 $ 17.51 Total intrinsic value of options exercised $ 110,916 $ 115,607 $ 155,202 Cash received from exercise of stock options 304,078 253,605 258,036 Tax benefit realized upon exercise of stock options 24,791 27,103 36,629 |
Schedule Of Non-Vested Shares Activity | Non-vested share and share unit activity for 2021 was as follows: (In thousands, except per share data) Number of Shares Weighted-Average Outstanding at beginning of year 4,131 $ 68.05 Granted 2,872 76.01 Vested (2,681) 68.24 Forfeited (678) 72.53 Outstanding at end of year 3,644 $ 73.35 For the Years Ended (In thousands, except for grant date fair values) 2021 2020 2019 Weighted average grant date fair values for shares granted during the year $ 76.01 $ 70.12 $ 66.49 Total fair value of shares vested during the year $ 202,543 $ 70,355 $ 30,558 |
Compensation Expense Recognized In The Condensed Consolidated Statements Of Operations | The amounts recognized in the consolidated statements of operations with respect to stock options, non-vested shares and share units and ASPP are as follows: For the Years Ended (In thousands) 2021 2020 2019 Stock option and non-vested share and share unit compensation expense $ 195,654 $ 153,449 $ 103,641 Associate stock purchase plan expense 5,786 5,478 6,053 Amounts capitalized in software development costs, net of amortization (4,199) (4,867) (410) Amounts charged against earnings, before income tax benefit $ 197,241 $ 154,060 $ 109,284 Amount of related income tax benefit recognized in earnings $ 38,623 $ 30,775 $ 20,967 |
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] | The components of AOCI, net of tax, were as follows: Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 29, 2018 $ (102,939) $ — $ (613) $ (103,552) Other comprehensive income (loss) before reclassifications (3,408) (13,078) 901 (15,585) Amounts reclassified from AOCI — 500 (23) 477 Balance at December 28, 2019 (106,347) (12,578) 265 (118,660) Other comprehensive income (loss) before reclassifications 12,897 (23,687) 194 (10,596) Amounts reclassified from AOCI — 8,477 (25) 8,452 Balance at December 31, 2020 (93,450) (27,788) 434 (120,804) Other comprehensive income (loss) before reclassifications (21,180) 4,241 (440) (17,379) Amounts reclassified from AOCI — 10,586 39 10,625 Balance at December 31, 2021 $ (114,630) $ (12,961) $ 33 $ (127,558) |
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] | The effects on net earnings of amounts reclassified from AOCI were as follows: (In thousands) Years Ended AOCI Component Location 2021 2020 2019 Unrealized loss on cash flow hedge Other income, net $ (13,150) $ (10,622) $ (624) Income taxes 2,564 2,145 124 Net of tax (10,586) (8,477) (500) Unrealized holding gain (loss) on available-for-sale investments Other income, net (48) 31 29 Income taxes 9 (6) (6) Net of tax (39) 25 23 Total amount reclassified, net of tax $ (10,625) $ (8,452) $ (477) |
Dividends Declared | Cash dividend activity in 2021, 2020, and 2019 was as follows: Date Declared Date of Record Payment Date Amount per Share May 29, 2019 June 18, 2019 July 26, 2019 $0.18 September 10, 2019 September 25, 2019 October 9, 2019 $0.18 December 12, 2019 December 27, 2019 January 9, 2020 $0.18 March 19, 2020 April 3, 2020 April 17, 2020 $0.18 May 21, 2020 June 5, 2020 July 17, 2020 $0.18 September 10, 2020 September 25, 2020 October 13, 2020 $0.18 December 10, 2020 December 28, 2020 January 12, 2021 $0.22 March 25, 2021 April 6, 2021 April 20, 2021 $0.22 May 19, 2021 June 28, 2021 July 13, 2021 $0.22 September 9, 2021 September 27, 2021 October 12, 2021 $0.22 December 9, 2021 December 27, 2021 January 11, 2022 $0.27 |
Commitments (Tables)
Commitments (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Aggregate Future Payments for Purchase Commitments | Aggregate future payments under these commitments are as follows: (In thousands) Purchase Obligations 2022 $ 54,308 2023 54,308 2024 40,933 2025 45,819 2026 52,054 2027 and thereafter 368,882 $ 616,304 |
Segment Reporting (Tables)
Segment Reporting (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Segment Reporting [Abstract] | |
Summary of the Operating Information | The following table presents a summary of our operating segments and other expense for 2021, 2020 and 2019: (In thousands) Domestic International Other Total 2021 Revenues $ 5,044,629 $ 720,195 $ — $ 5,764,824 Costs of revenue 887,343 113,674 — 1,001,017 Operating expenses 2,358,897 277,308 1,419,326 4,055,531 Total costs and expenses 3,246,240 390,982 1,419,326 5,056,548 Operating earnings (loss) $ 1,798,389 $ 329,213 $ (1,419,326) $ 708,276 (In thousands) Domestic International Other Total 2020 Revenues $ 4,879,769 $ 626,019 $ — $ 5,505,788 Costs of revenue 854,574 78,367 — 932,941 Operating expenses 2,339,624 242,991 1,296,188 3,878,803 Total costs and expenses 3,194,198 321,358 1,296,188 4,811,744 Gain on sale of businesses — — 220,523 220,523 Operating earnings (loss) $ 1,685,571 $ 304,661 $ (1,075,665) $ 914,567 (In thousands) Domestic International Other Total 2019 Revenues $ 5,038,127 $ 654,471 $ — $ 5,692,598 Costs of revenue 967,035 104,006 — 1,071,041 Operating expenses 2,398,422 276,914 1,345,552 4,020,888 Total costs and expenses 3,365,457 380,920 1,345,552 5,091,929 Operating earnings (loss) $ 1,672,670 $ 273,551 $ (1,345,552) $ 600,669 |
Basis of Presentation, Nature_3
Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Internal use software | |
Property, Plant and Equipment [Line Items] | |
Finite-Lived Intangible Asset, Useful Life | 5 years |
Basis of Presentation, Nature_4
Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies Presentation (Details) - USD ($) $ in Millions | Jan. 19, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 |
Statement Presentation [Line Items] | |||||
Postemployment Benefits, Period Expense | $ 53 | $ 20 | $ 52 | ||
Description of New Accounting Pronouncements Not yet Adopted [Text Block] | Recently Issued Accounting Pronouncements Reference Rate Reform. The Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting in March 2020 and ASU 2021-01, Reference Rate Reform (Topic 848): Scope in January 2021. Such guidance provides optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform, such as the upcoming discontinuance of the London Interbank Offered Rate ("LIBOR"). The accommodations within this guidance may be applied prospectively from the beginning of our 2020 first quarter through December 31, 2022. We are currently evaluating the effect that this guidance may have on our contracts that reference LIBOR, specifically, our Fourth Amended and Restated Credit Agreement and related interest rate swap. As of the date of this filing, we have not elected to apply any of the provisions of this guidance. Business Combinations. The FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers in October 2021. Such guidance amends the recognition and measurement principles that apply to business combinations to require that an entity recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. ASU 2021-08 is effective for the Company in the first quarter of 2023, with early adoption permitted. The standard requires prospective application to business combinations occurring on or after the date of adoption. As of the date of this filing, we have not determined if we will early adopt. | ||||
CARES Act federal payroll taxes remitted | $ 38 | ||||
CARES Act Deferred Remittance of Employer Payroll Tax included in "Accrued payroll and tax withholdings" | 38 | ||||
CARES Act Deferred Remittance of Employer Payroll Tax included in "Other liabilities" | 38 | ||||
CARES Act federal payroll taxes expected to be remitted | 38 | ||||
Subsequent Event [Member] | |||||
Statement Presentation [Line Items] | |||||
Subsequent Event, Description | On December 20, 2021, we entered into an Agreement and Plan of Merger (as it may be amended or supplemented from time to time, the "Merger Agreement") with Cedar Acquisition Corporation ("Merger Subsidiary"), which is a wholly owned subsidiary of OC Acquisition LLC ("Parent"), Parent, which is a wholly owned subsidiary of Oracle Corporation ("Oracle"), and (solely with respect to performance of its obligations set forth in certain specified sections thereof) Oracle. Pursuant to the Merger Agreement, on January 19, 2022, Oracle commenced a cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of our common stock for a purchase price of $95.00 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. If the Offer is completed, Merger Subsidiary will merge with and into Cerner (the "Merger") and we will become a wholly owned indirect subsidiary of Oracle. As a result of the Merger, the shares of our common stock will cease to be publicly held. Completion of the Merger is subject to certain conditions, including but not limited to, a) shareholders holding a majority of the outstanding shares of our common stock tendering their shares in the Offer, and b) receipt of certain regulatory approvals, including the expiration or termination of the waiting periods or the obtaining of the required affirmative approvals applicable to the transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and certain foreign antitrust and foreign direct investment laws. We have agreed to various customary covenants and agreements in the Merger Agreement, including with respect to the operation of our business prior to the closing of the transaction, such as restrictions on making certain acquisitions and divestitures, entering into certain contracts, incurring certain indebtedness and making certain capital expenditures, paying dividends in excess of our regular quarterly dividend, issuing or repurchasing stock and taking other specified actions. | On February 15, 2022, we repaid our $225 million of Series 2015-A Notes due February 15, 2022. | |||
Employee Separation Costs [Member] | |||||
Statement Presentation [Line Items] | |||||
Restructuring Charges | $ 56 | 22 | 34 | ||
Contract Termination [Member] | |||||
Statement Presentation [Line Items] | |||||
Restructuring Charges | $ 29 | $ 66 |
Revenue from Contract with Cu_3
Revenue from Contract with Customer Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Disaggregation of Revenue [Line Items] | |||
Revenue | $ 5,764,824 | $ 5,505,788 | $ 5,692,598 |
Transferred over Time [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 5,416,952 | 5,142,674 | 5,166,125 |
Transferred at Point in Time [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 347,872 | 363,114 | 526,473 |
Revenue, Licensed Software, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 725,656 | 656,219 | 680,585 |
Revenue, Technology Resale, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 184,672 | 196,591 | 246,885 |
Revenue, Subscriptions, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 382,858 | 378,208 | 358,715 |
Revenue, Professional Services, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 2,116,491 | 1,930,445 | 1,992,478 |
Revenue, Managed Services, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 1,288,453 | 1,245,427 | 1,213,900 |
Revenue, Support and Maintenance Services, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 1,032,907 | 1,070,779 | 1,104,638 |
Revenue, Reimbursement Revenue [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 33,787 | 28,119 | 95,397 |
Domestic Segment [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 5,044,629 | 4,879,769 | 5,038,127 |
Domestic Segment [Member] | Transferred over Time [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 4,736,395 | 4,557,358 | 4,565,172 |
Domestic Segment [Member] | Transferred at Point in Time [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 308,234 | 322,411 | 472,955 |
Domestic Segment [Member] | Revenue, Licensed Software, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 671,926 | 604,707 | 628,958 |
Domestic Segment [Member] | Revenue, Technology Resale, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 163,280 | 173,264 | 225,076 |
Domestic Segment [Member] | Revenue, Subscriptions, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 365,936 | 354,023 | 333,298 |
Domestic Segment [Member] | Revenue, Professional Services, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 1,817,213 | 1,717,873 | 1,760,532 |
Domestic Segment [Member] | Revenue, Managed Services, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 1,143,188 | 1,120,939 | 1,098,695 |
Domestic Segment [Member] | Revenue, Support and Maintenance Services, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 849,428 | 881,778 | 904,204 |
Domestic Segment [Member] | Revenue, Reimbursement Revenue [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 33,658 | 27,185 | 87,364 |
International Segment [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 720,195 | 626,019 | 654,471 |
International Segment [Member] | Transferred over Time [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 680,557 | 585,316 | 600,953 |
International Segment [Member] | Transferred at Point in Time [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 39,638 | 40,703 | 53,518 |
International Segment [Member] | Revenue, Licensed Software, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 53,730 | 51,512 | 51,627 |
International Segment [Member] | Revenue, Technology Resale, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 21,392 | 23,327 | 21,809 |
International Segment [Member] | Revenue, Subscriptions, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 16,922 | 24,185 | 25,417 |
International Segment [Member] | Revenue, Professional Services, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 299,278 | 212,572 | 231,946 |
International Segment [Member] | Revenue, Managed Services, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 145,265 | 124,488 | 115,205 |
International Segment [Member] | Revenue, Support and Maintenance Services, Net [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | 183,479 | 189,001 | 200,434 |
International Segment [Member] | Revenue, Reimbursement Revenue [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | $ 129 | $ 934 | $ 8,033 |
Revenue from Contract with Cu_4
Revenue from Contract with Customer Performance Obligations (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue Recognition [Line Items] | ||
Revenue [Policy Text Block] | We enter into contracts with customers that may include various combinations of our software solutions and related services, which are generally capable of being distinct and accounted for as separate performance obligations. Performance obligations that are not distinct at contract inception are combined. Contracts that include software customization may result in the combination of the customization services with the software license as one distinct performance obligation.The predominant model of customer procurement involves multiple deliverables and includes a software license agreement, project-related implementation and consulting services, software support, hosting services, and computer hardware. We allocate revenues to each performance obligation within an arrangement based on estimated relative stand-alone selling price. Revenue is then recognized for each performance obligation upon transfer of control of the software solution or services to the customer in an amount that reflects the consideration we expect to receive. | |
Revenue, Remaining Performance Obligation, Amount | $ 13,260 | $ 13,040 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation | we expect to recognize approximately 31% of the revenue over the next 12 months and the remainder thereafter | |
Perpetual Software Licenses [Member] | ||
Revenue Recognition [Line Items] | ||
Revenue, Performance Obligation, Description of Timing | Perpetual software licenses - We recognize perpetual software license revenues when control of such licenses are transferred to the client ("point in time"). We determine the amount of consideration allocated to this performance obligation using the residual approach | |
Software as a Service [Member] | ||
Revenue Recognition [Line Items] | ||
Revenue, Performance Obligation, Description of Timing | Software as a service - We recognize software as a service ratably over the related hosting period ("over time") | |
Time-based Software and Content License Fees [Member] | ||
Revenue Recognition [Line Items] | ||
Revenue, Performance Obligation, Description of Timing | Time-based software and content license fees - We recognize a license component of time-based software and content license fees upon delivery to the client ("point in time") and a non-license component (i.e. support) ratably over the respective contract term ("over time") | |
Remote Hosting Recurring Services [Member] | ||
Revenue Recognition [Line Items] | ||
Revenue, Performance Obligation, Description of Timing | Hosting - Remote hosting recurring services are recognized ratably over the hosting service period ("over time"). Certain of our hosting arrangements contain fees deemed to be a "material right" under Topic 606. We recognize such fees over the term that will likely affect the client's decision about whether to renew the related hosting service ("over time") | |
Services [Member] | ||
Revenue Recognition [Line Items] | ||
Revenue, Performance Obligation, Description of Timing | Services - We recognize revenue for fixed fee services arrangements over time, utilizing a labor hours input method. For fee-for-service arrangements, we recognize revenue over time as hours are worked at the rates clients are invoiced, utilizing the "as invoiced" practical expedient available in Topic 606. For stand-ready services arrangements, we recognize revenue ratably over the related service period | |
Support and Maintenance [Member] | ||
Revenue Recognition [Line Items] | ||
Revenue, Performance Obligation, Description of Timing | Support and maintenance - We recognize support and maintenance fees ratably over the related contract period ("over time") | |
Hardware [Member] | ||
Revenue Recognition [Line Items] | ||
Revenue, Performance Obligation, Description of Timing | Hardware - We recognize hardware revenues when control of such hardware/devices is transferred to the client ("point in time") | |
Transaction Processing [Member] | ||
Revenue Recognition [Line Items] | ||
Revenue, Performance Obligation, Description of Timing | Transaction processing - We recognize transaction processing revenues ratably as we provide such services ("over time") |
Revenue from Contract with Cu_5
Revenue from Contract with Customer (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Revenue from Contract with Customer [Abstract] | |||
Segment Reporting, Disclosure of Major Customers | Revenues attributable to our relationships (as the prime contractor or a subcontractor) with U.S. government agencies, within our Domestic segment, comprised 20%, 18% and 13% of our consolidated revenues for 2021, 2020 and 2019, respectively. Amounts due in connection with these relationships comprised 15% and 13% of client receivables as of December 31, 2021 and December 31, 2020, respectively. | ||
Contract with Customer, Liability, Explanation of Change | substantially all of our contract liability balance at the beginning of each respective year was recognized in revenues during that year | ||
Capitalized Contract Cost, Net | $ 91 | $ 88 | |
Capitalized Contract Cost, Amortization | $ 39 | $ 38 | $ 41 |
Revenue, Judgment | Our contracts with clients typically include various combinations of our software solutions and related services. Determining whether such software solutions and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment | ||
Revenue, Information Used to Allocate Transaction Price | Contract transaction price is allocated to distinct performance obligations using estimated stand-alone selling price | ||
Revenue, Information Used to Determine Transaction Price | We determine stand-alone selling price maximizing observable inputs such as stand-alone sales when they exist or substantive renewal prices charged to clients. In instances where stand-alone selling price is not observable, we utilize an estimate of stand-alone selling price. Such estimates are derived from various methods that include: cost plus margin, historical pricing practices, and the residual approach. Judgment may be required to determine standalone selling prices for each performance obligation and whether it depicts the amount we expect to receive in exchange for the related good or service. |
Receivables (Narrative) (Detail
Receivables (Narrative) (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Receivables [Abstract] | ||
Client cash collections | $ 6,130 | $ 5,700 |
Accounts Receivable, after Allowance for Credit Loss, Noncurrent | $ 16 | $ 17 |
Accounting Standards Update 2016-13 [Member] | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
New Accounting Pronouncement or Change in Accounting Principle, Description | In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which provides a new impairment model for certain financial assets that is based on expected losses rather than incurred losses. Such guidance impacts how we determine our allowance for estimated uncollectible client receivables. The standard requires use of the modified retrospective (cumulative effect) transition approach as of the beginning of the first reporting period in which the guidance was effective, which for the Company was the first quarter of 2020. Under this transition method, the cumulative effect from prior periods upon applying this new guidance was recognized in our consolidated balance sheets as of December 29, 2019. We did not recast comparative periods. |
Receivables (Summary Of Net Rec
Receivables (Summary Of Net Receivables) (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Receivables [Abstract] | ||
Client receivables | $ 1,307,167 | $ 1,322,278 |
Less: Provision for expected credit losses | 145,806 | 153,566 |
Total receivables, net | $ 1,161,361 | $ 1,168,712 |
Receivables Schedule of Valuati
Receivables Schedule of Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | Dec. 29, 2018 | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | ||||
Accounts Receivable, Allowance for Credit Loss | $ 206,912 | $ 192,130 | $ 171,414 | $ 128,410 |
Accounts Receivable, Credit Loss Expense (Reversal) | 39,791 | 85,802 | 57,167 | |
Accounts receivable, allowance for Credit Loss, Reclassifications to non-current | 0 | |||
Accounts Receivable, Allowance for Credit Loss, Writeoff | (25,009) | (69,692) | (14,163) | |
Current Expected Credit Losses | ||||
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | ||||
Accounts Receivable, Allowance for Credit Loss | 145,806 | 153,566 | 106,075 | 64,561 |
Accounts Receivable, Credit Loss Expense (Reversal) | 39,791 | 65,099 | 57,167 | |
Accounts receivable, allowance for Credit Loss, Reclassifications to non-current | (26,480) | |||
Accounts Receivable, Allowance for Credit Loss, Writeoff | (21,071) | (22,214) | (15,653) | |
Non-current Expected Credit Losses | ||||
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | ||||
Accounts Receivable, Allowance for Credit Loss | 61,106 | 38,564 | 65,339 | $ 63,849 |
Accounts Receivable, Credit Loss Expense (Reversal) | 0 | 20,703 | 0 | |
Accounts receivable, allowance for Credit Loss, Reclassifications to non-current | 26,480 | |||
Accounts Receivable, Allowance for Credit Loss, Writeoff | $ (3,938) | (47,478) | $ (1,490) | |
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2016-13 [Member] | ||||
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment | 4,606 | |||
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2016-13 [Member] | Current Expected Credit Losses | ||||
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment | 4,606 | |||
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2016-13 [Member] | Non-current Expected Credit Losses | ||||
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment | $ 0 |
Cumulative Effect Transition (D
Cumulative Effect Transition (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Receivables, Net, Current | $ 1,161,361 | $ 1,168,712 |
Retained Earnings (Accumulated Deficit) | $ 6,751,692 | 6,475,551 |
Accounting Standards Update 2016-13 [Member] | Cumulative Effect, Period of Adoption, Adjustment | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Receivables, Net, Current | (4,606) | |
Retained Earnings (Accumulated Deficit) | $ (4,606) |
Investments (Narrative) (Detail
Investments (Narrative) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Investments [Abstract] | |||
Equity Securities without Readily Determinable Fair Value, Amount | $ 406,000 | $ 361,000 | |
Equity Securities, FV-NI | $ 14,000 | ||
Gain on sale of equity investment | 0 | 75,834 | 15,509 |
Unrealized gain on equity investment | 0 | 0 | 14,112 |
Equity Method Investments | 25,000 | 12,000 | |
Proceeds from Sale of Debt and Equity Securities, FV-NI, Held-for-investment | 90,000 | ||
Proceeds from Sale of Debt Securities, Available-for-sale | $ 420,000 | $ 71,000 | $ 233,000 |
Investments (Details)
Investments (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Debt Securities, Available-for-sale [Line Items] | ||
Adjusted Cost | $ 551,509 | $ 717,043 |
Gross Unrealized Gains | 18 | 411 |
Gross Unrealized Losses | (266) | (120) |
Debt Securities, Available-for-sale | 551,261 | 717,334 |
Cash equivalents [Member] | ||
Debt Securities, Available-for-sale [Line Items] | ||
Adjusted Cost | 267,621 | 137,783 |
Debt Securities, Available-for-sale | 267,621 | 137,783 |
Cash equivalents [Member] | Money market funds [Member] | ||
Debt Securities, Available-for-sale [Line Items] | ||
Adjusted Cost | 149,429 | 40,027 |
Debt Securities, Available-for-sale | 149,429 | 40,027 |
Cash equivalents [Member] | Time deposits [Member] | ||
Debt Securities, Available-for-sale [Line Items] | ||
Adjusted Cost | 35,342 | 36,756 |
Debt Securities, Available-for-sale | 35,342 | 36,756 |
Cash equivalents [Member] | Commercial paper [Member] | ||
Debt Securities, Available-for-sale [Line Items] | ||
Adjusted Cost | 77,850 | 61,000 |
Debt Securities, Available-for-sale | 77,850 | 61,000 |
Cash equivalents [Member] | Government and corporate bonds [Member] | ||
Debt Securities, Available-for-sale [Line Items] | ||
Adjusted Cost | 5,000 | |
Debt Securities, Available-for-sale | 5,000 | |
Short-term investments [Member] | ||
Debt Securities, Available-for-sale [Line Items] | ||
Adjusted Cost | 252,721 | 442,277 |
Gross Unrealized Gains | 18 | 259 |
Gross Unrealized Losses | (117) | (63) |
Debt Securities, Available-for-sale | 252,622 | 442,473 |
Short-term investments [Member] | Time deposits [Member] | ||
Debt Securities, Available-for-sale [Line Items] | ||
Adjusted Cost | 25,598 | 28,302 |
Debt Securities, Available-for-sale | 25,598 | 28,302 |
Short-term investments [Member] | Commercial paper [Member] | ||
Debt Securities, Available-for-sale [Line Items] | ||
Adjusted Cost | 57,000 | 264,000 |
Gross Unrealized Gains | 12 | |
Gross Unrealized Losses | (14) | (19) |
Debt Securities, Available-for-sale | 56,986 | 263,993 |
Short-term investments [Member] | Government and corporate bonds [Member] | ||
Debt Securities, Available-for-sale [Line Items] | ||
Adjusted Cost | 170,123 | 149,975 |
Gross Unrealized Gains | 18 | 247 |
Gross Unrealized Losses | (103) | (44) |
Debt Securities, Available-for-sale | 170,038 | 150,178 |
Long-term investments [Member] | Government and corporate bonds [Member] | ||
Debt Securities, Available-for-sale [Line Items] | ||
Adjusted Cost | 31,167 | 136,983 |
Gross Unrealized Gains | 152 | |
Gross Unrealized Losses | (149) | (57) |
Debt Securities, Available-for-sale | $ 31,018 | $ 137,078 |
Property and Equipment (Details
Property and Equipment (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Property, Plant and Equipment [Abstract] | |||
Depreciation and leasehold amortization expense | $ 362,000 | $ 365,000 | $ 347,000 |
Impairment of Long-Lived Assets to be Disposed of | 80,000 | ||
Property, Plant and Equipment [Line Items] | |||
Impairment of Long-Lived Assets to be Disposed of | 80,000 | ||
Property and equipment held and used | 1,566,870 | 1,804,083 | |
Real Estate Held-for-sale | 89,301 | 0 | |
Property, Plant and Equipment, Net | 1,656,171 | $ 1,804,083 | |
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment | 89,000 | ||
Sales and client service | |||
Property, Plant and Equipment [Abstract] | |||
Impairment of Long-Lived Assets to be Disposed of | 78,000 | ||
Property, Plant and Equipment [Line Items] | |||
Impairment of Long-Lived Assets to be Disposed of | 78,000 | ||
General and Administrative Expense | |||
Property, Plant and Equipment [Abstract] | |||
Impairment of Long-Lived Assets to be Disposed of | 2,000 | ||
Property, Plant and Equipment [Line Items] | |||
Impairment of Long-Lived Assets to be Disposed of | $ 2,000 |
Property and Equipment Schedule
Property and Equipment Schedule of Property and Equipment (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | $ 3,500,493 | $ 3,699,224 |
Less accumulated depreciation and leasehold amortization | 1,933,623 | 1,895,141 |
Total property and equipment, net | 1,656,171 | 1,804,083 |
Computer and communications equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 1,981,488 | 1,939,517 |
Land, buildings and improvements | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 1,180,042 | 1,403,835 |
Leasehold improvements | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 202,283 | 208,496 |
Furniture and fixtures | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 116,236 | 146,351 |
Other equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | $ 20,444 | $ 1,025 |
Property and Equipment Schedu_2
Property and Equipment Schedule of Useful Lives (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Computer and communications equipment | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property and equipment, useful life | 1 year |
Computer and communications equipment | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property and equipment, useful life | 5 years |
Land, buildings and improvements | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property and equipment, useful life | 12 years |
Land, buildings and improvements | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property and equipment, useful life | 50 years |
Leasehold improvements | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property and equipment, useful life | 1 year |
Leasehold improvements | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property and equipment, useful life | 15 years |
Furniture and fixtures | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property and equipment, useful life | 5 years |
Furniture and fixtures | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property and equipment, useful life | 12 years |
Other equipment | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property and equipment, useful life | 3 years |
Other equipment | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property and equipment, useful life | 20 years |
Leases (Narrative) (Details)
Leases (Narrative) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Lessee Disclosure [Abstract] | |||
Lessee, Operating Lease, Description | we are the lessee under operating leases for real estate (office, data center, and warehouse space) and certain dedicated fiber optic lines within our infrastructure | ||
Lessee, Operating Lease, Variable Lease Payment, Terms and Conditions | Generally, variable lease payments under these operating lease agreements relate to amounts based on changes to an index or rate (i.e. percentage change in the consumer price index) | ||
Operating Lease, Cost | $ 31 | $ 37 | $ 37 |
Variable Lease, Cost | $ 1 | ||
Operating Lease, Weighted Average Remaining Lease Term | 6 years 11 months 19 days | ||
Operating Lease, Weighted Average Discount Rate, Percent | 3.30% |
Leases Cumulative Effect Transi
Leases Cumulative Effect Transition (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 30, 2018 | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Right-of-use assets | $ 82,940 | $ 104,536 | |
Other current liabilities | 223,350 | 229,764 | |
Other liabilities | $ 121,005 | $ 157,799 | |
Accounting Standards Update 2016-02 [Member] | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
New Accounting Pronouncement or Change in Accounting Principle, Description | In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which introduced a new accounting model that requires most leases to be reported on the balance sheet. It also established disclosure requirements, which are more extensive than those required under prior U.S. GAAP. The standard required use of the modified retrospective (cumulative effect) transition approach and was effective for the Company in the first quarter of 2019. We selected the effective date of ASU 2016-02 as the date of initial application on transition, as permitted by ASU 2016-02, as amended ("Topic 842"). Under this transition method, the cumulative effect from prior periods upon applying the new guidance to arrangements containing leases was recognized in our consolidated balance sheets as of December 30, 2018. We did not recast comparative periods | ||
Right-of-use assets | $ 129,652 | ||
Prepaid Expense and Other Assets | 3,968 | ||
Other current liabilities | 22,767 | ||
Other liabilities | $ 110,853 |
Leases Schedule of Operating Le
Leases Schedule of Operating Lease Amounts Included in the Balance Sheet (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Schedule of Operating Lease Amounts Included in the Balance Sheet [Line Items] | ||
Right-of-use assets | $ 82,940 | $ 104,536 |
Operating Lease, Liability, Current | Other current liabilities | Other current liabilities |
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Other liabilities | Other liabilities |
Leases Schedule of Aggregate Fu
Leases Schedule of Aggregate Future Minimum Payments for Non-Cancelable Operating Leases (Details) $ in Thousands | Dec. 31, 2021USD ($) |
Operating Leases, Future Minimum Payments [Line Items] | |
Aggregate future payments | $ 109,237 |
Impact of discounting | (14,383) |
Other Liabilities | |
Operating Leases, Future Minimum Payments [Line Items] | |
Operating Lease, Liability | 94,854 |
Future Minimum Payments Due | |
Operating Leases, Future Minimum Payments [Line Items] | |
2022 | 27,694 |
2023 | 20,826 |
2024 | 13,824 |
2025 | 8,884 |
2026 | 5,978 |
2027 and thereafter | $ 32,031 |
Software Development Costs Sche
Software Development Costs Schedule of Software Development Costs, Net (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Schedule of Software Development Costs [Line Items] | ||
Capitalized Computer Software, Gross | $ 3,226,672 | $ 2,995,644 |
Capitalized Computer Software, Accumulated Amortization | 2,226,315 | 1,986,295 |
Capitalized Computer Software, Net | 1,000,357 | 1,009,349 |
Software to sold, leased or marketed [Member] | ||
Schedule of Software Development Costs [Line Items] | ||
Capitalized Computer Software, Gross | 2,751,960 | 2,610,476 |
Capitalized Computer Software, Accumulated Amortization | 1,985,051 | 1,788,019 |
Software delivered exclusively as a service [Member] | ||
Schedule of Software Development Costs [Line Items] | ||
Capitalized Computer Software, Gross | 474,712 | 385,168 |
Capitalized Computer Software, Accumulated Amortization | $ 241,264 | $ 198,276 |
Software Development Costs Sc_2
Software Development Costs Schedule of Capitalized Software, Future Amortization Expense (Details) $ in Thousands | Dec. 31, 2021USD ($) |
Research and Development [Abstract] | |
Capitalized Computer Software, Amortization Expense, Next Twelve Months | $ 280,626 |
Capitalized Computer Software, Amortization Expense, Year Two | 247,172 |
Capitalized Computer Software, Amortization Expense, Year Three | 201,507 |
Capitalized Computer Software, Amortization Expense, Year Four | 146,610 |
Capitalized Computer Software, Amortization Expense, Year Five | $ 90,212 |
Software Development Costs (Det
Software Development Costs (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Research and Development [Abstract] | |||
Software development costs | $ 828,502 | $ 796,971 | $ 783,593 |
Capitalized software development costs | (308,026) | (295,277) | (273,871) |
Amortization of capitalized software development costs | (261,798) | (247,313) | (227,414) |
Capitalized Computer Software, Impairments | 53,721 | 0 | 0 |
Total software development expense | $ 835,995 | $ 749,007 | $ 737,136 |
Software Development Costs (Nar
Software Development Costs (Narrative) (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Research and Development [Abstract] | |||
Capitalized Computer Software, Impairments | $ 53,721 | $ 0 | $ 0 |
Business Acquisition (Details)
Business Acquisition (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
AbleVets, LLC. [Member] | |||
Business Acquisition [Line Items] | |||
Business Acquisition, Description of Acquired Entity | AbleVets is a health IT engineering and consulting company specializing in cybersecurity, cloud and system development solutions for federal organizations. | ||
Business Combination, Reason for Business Combination | We believe this acquisition enhanced our resource capabilities and growth opportunities within our federal business. | ||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 8 years | ||
Business Combination, Consideration Transferred | $ 76 | ||
Business Acquisition, Effective Date of Acquisition | Oct. 25, 2019 | ||
Business Acquisition, Name of Acquired Entity | AbleVets, LLC | ||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 8 years | ||
Business Acquisition, Effective Date of Acquisition | Oct. 25, 2019 | ||
Business Acquisition, Name of Acquired Entity | AbleVets, LLC | ||
Business Acquisition, Description of Acquired Entity | AbleVets is a health IT engineering and consulting company specializing in cybersecurity, cloud and system development solutions for federal organizations. | ||
Business Combination, Reason for Business Combination | We believe this acquisition enhanced our resource capabilities and growth opportunities within our federal business. | ||
Business Combination, Consideration Transferred | $ 76 | ||
2020 Acquisitions [Member] | |||
Business Acquisition [Line Items] | |||
Business Acquisition, Goodwill, Expected Tax Deductible Amount | $ 4 | ||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 8 years | ||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 8 years | ||
Business Acquisition, Goodwill, Expected Tax Deductible Amount | $ 4 | ||
Kantar Health | |||
Business Acquisition [Line Items] | |||
Business Acquisition, Description of Acquired Entity | we acquired Kantar Health, a division of Kantar Group. Kantar Health provides data, analytics, commercial research, and consulting services to the life sciences industry. | ||
Business Combination, Reason for Business Combination | We believe this acquisition complements our existing Data-as-a-Service efforts as it provides a meaningful entry into the pharmaceutical market through Kantar Health's existing clients and their leadership team with important industry experience and relationships. | ||
Business Acquisition, Goodwill, Expected Tax Deductible Amount | $ 170 | ||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 13 years | ||
Business Combination, Consideration Transferred | $ 375 | ||
Business Acquisition, Effective Date of Acquisition | Apr. 1, 2021 | ||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 13 years | ||
Business Acquisition, Goodwill, Expected Tax Deductible Amount | $ 170 | ||
Business Acquisition, Effective Date of Acquisition | Apr. 1, 2021 | ||
Business Acquisition, Description of Acquired Entity | we acquired Kantar Health, a division of Kantar Group. Kantar Health provides data, analytics, commercial research, and consulting services to the life sciences industry. | ||
Business Combination, Reason for Business Combination | We believe this acquisition complements our existing Data-as-a-Service efforts as it provides a meaningful entry into the pharmaceutical market through Kantar Health's existing clients and their leadership team with important industry experience and relationships. | ||
Business Combination, Consideration Transferred | $ 375 | ||
April 2020 Acquisition | |||
Business Acquisition [Line Items] | |||
Business Acquisition, Description of Acquired Entity | consulting company specializing in providing cybersecurity solutions to clients in the healthcare industry | ||
Business Combination, Reason for Business Combination | We believe this acquisition enhanced our resource capabilities and growth opportunities for our cybersecurity solution offerings | ||
Business Combination, Consideration Transferred | $ 34 | ||
Business Acquisition, Effective Date of Acquisition | Apr. 1, 2020 | ||
Business Acquisition, Effective Date of Acquisition | Apr. 1, 2020 | ||
Business Acquisition, Description of Acquired Entity | consulting company specializing in providing cybersecurity solutions to clients in the healthcare industry | ||
Business Combination, Reason for Business Combination | We believe this acquisition enhanced our resource capabilities and growth opportunities for our cybersecurity solution offerings | ||
Business Combination, Consideration Transferred | $ 34 | ||
October 2020 Acquisition | |||
Business Acquisition [Line Items] | |||
Business Acquisition, Description of Acquired Entity | software company that offered a patient referral management solution to clients within the healthcare industry | ||
Business Combination, Reason for Business Combination | We believe this acquisition enhanced our portfolio of offerings on our HealtheIntent platform | ||
Business Combination, Consideration Transferred | $ 15 | ||
Business Acquisition, Effective Date of Acquisition | Oct. 19, 2020 | ||
Business Acquisition, Effective Date of Acquisition | Oct. 19, 2020 | ||
Business Acquisition, Description of Acquired Entity | software company that offered a patient referral management solution to clients within the healthcare industry | ||
Business Combination, Reason for Business Combination | We believe this acquisition enhanced our portfolio of offerings on our HealtheIntent platform | ||
Business Combination, Consideration Transferred | $ 15 |
Business Acquisition Schedule o
Business Acquisition Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Business Acquisition [Line Items] | |||
Goodwill | $ 1,131,121 | $ 914,520 | $ 883,158 |
Goodwill, Acquired During Period | $ 226,232 | $ 33,709 | |
Business Combinations Policy [Policy Text Block] | Our acquisition of Kantar Health was treated as a purchase in accordance with ASC 805, Business Combinations | ||
Schedule of Business Acquisitions, by Acquisition [Table Text Block] | The final allocation of purchase price was as follows: (In thousands) Allocation Amount Cash and cash equivalents $ 15,311 Receivables, net 32,616 Prepaid expenses and other 8,881 Property and equipment, net 1,198 Right-of-use assets 1,939 Goodwill 226,232 Intangible assets, net: Customer relationships 143,100 Existing technologies 39,700 Trade names 10,200 Other assets 428 Accounts payable (36,748) Deferred revenue (35,698) Accrued payroll and tax withholdings (11,172) Other current liabilities (3,189) Deferred income taxes (11,733) Other liabilities (10,250) Total purchase price $ 370,815 | The aggregate final allocation of purchase price for our 2020 acquisitions was as follows: (In thousands) Allocation Amount Receivables, net $ 2,313 Inventory 863 Prepaid expenses and other 331 Property and equipment, net 114 Right-of-use assets 683 Goodwill 33,709 Intangible assets, net 16,510 Other assets 179 Accounts payable (880) Deferred revenue (3,158) Accrued payroll and tax withholdings (501) Other current liabilities (713) Deferred income taxes (374) Total purchase price $ 49,076 | The final allocation of purchase price was as follows: (In thousands) Allocation Amount Cash and cash equivalents $ 471 Receivables, net 11,690 Prepaid expenses and other 911 Property and equipment, net 1,240 Right-of-use assets 8,448 Goodwill 37,815 Intangible assets, net 37,402 Accounts payable (5,244) Deferred revenue (157) Accrued payroll and tax withholdings (5,812) Other current liabilities (2,994) Other liabilities (8,016) Total purchase price $ 75,754 |
AbleVets, LLC. [Member] | |||
Business Acquisition [Line Items] | |||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents | $ 471 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables | 11,690 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets | 911 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | 1,240 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-use Assets | 8,448 | ||
Goodwill | 37,815 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangible Assets | 37,402 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable | (5,244) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue | (157) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Payroll and Tax Withholdings | (5,812) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities | (2,994) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities | (8,016) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | $ 75,754 | ||
Business Acquisition, Effective Date of Acquisition | Oct. 25, 2019 | ||
Business Acquisition, Description of Acquired Entity | AbleVets is a health IT engineering and consulting company specializing in cybersecurity, cloud and system development solutions for federal organizations. | ||
Business Combination, Reason for Business Combination | We believe this acquisition enhanced our resource capabilities and growth opportunities within our federal business. | ||
Business Combination, Consideration Transferred | $ 76,000 | ||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 8 years | ||
2020 Acquisitions [Member] | |||
Business Acquisition [Line Items] | |||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables | $ 2,313 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory | 863 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets | 331 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | 114 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-use Assets | 683 | ||
Goodwill | 33,709 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangible Assets | 16,510 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets | 179 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable | (880) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue | (3,158) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Payroll and Tax Withholdings | (501) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities | (713) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities | (374) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | $ 49,076 | ||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 8 years | ||
Business Acquisition, Goodwill, Expected Tax Deductible Amount | $ 4,000 | ||
Kantar Health | |||
Business Acquisition [Line Items] | |||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents | $ 15,311 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables | 32,616 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets | 8,881 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | 1,198 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-use Assets | 1,939 | ||
Goodwill | 226,232 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets | 428 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable | (36,748) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue | (35,698) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Payroll and Tax Withholdings | 11,172 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities | (3,189) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities | (10,250) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities | (11,733) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | $ 370,815 | ||
Business Acquisition, Effective Date of Acquisition | Apr. 1, 2021 | ||
Business Acquisition, Description of Acquired Entity | we acquired Kantar Health, a division of Kantar Group. Kantar Health provides data, analytics, commercial research, and consulting services to the life sciences industry. | ||
Business Combination, Reason for Business Combination | We believe this acquisition complements our existing Data-as-a-Service efforts as it provides a meaningful entry into the pharmaceutical market through Kantar Health's existing clients and their leadership team with important industry experience and relationships. | ||
Business Combination, Goodwill Recognized, Description | These factors, combined with the synergies and economies of scale expected, are the basis for the acquisition and comprise the resulting goodwill recorded. | ||
Business Combination, Consideration Transferred | $ 375,000 | ||
Business Acquisition, Date of Acquisition Agreement | Dec. 16, 2020 | ||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 13 years | ||
Goodwill, Acquired During Period | $ 226,000 | ||
Business Acquisition, Goodwill, Expected Tax Deductible Amount | 170,000 | ||
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | 148,000 | ||
Kantar Health | Customer Relationships | |||
Business Acquisition [Line Items] | |||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangible Assets | 143,100 | ||
Kantar Health | Technology-Based Intangible Assets | |||
Business Acquisition [Line Items] | |||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangible Assets | 39,700 | ||
Kantar Health | Trade Names | |||
Business Acquisition [Line Items] | |||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangible Assets | $ 10,200 |
Gain on sale of businesses (Det
Gain on sale of businesses (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | Jul. 01, 2020 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Gain on sale of businesses | $ 0 | $ 220,523 | $ 0 | |
Sale of businesses | $ 0 | 229,471 | $ 0 | |
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net | $ 8,646 | |||
Disposal Group, Including Discontinued Operation, Inventory, Current | 65 | |||
Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current | 5,993 | |||
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent | 340 | |||
Disposal Group, Including Discontinued Operation, Right-of-Use Asset | 554 | |||
Disposal Group, Including Discontinued Operation, Capitalized Computer Software, Net | 5,532 | |||
Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent | 7,692 | |||
Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent | 3,687 | |||
Disposal Group, Including Discontinued Operation, Accounts Payable, Current | (2,763) | |||
Disposal Group, Including Discontinued Operation, Deferred Revenue, Current | (16,756) | |||
Disposal Group, Including Discontinued Operation, Employee-related Liabilities, Current | (4,545) | |||
Disposal Group, Including Discontinued Operation, Other Liabilities, Current | (511) | |||
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Compugroup Medical SE & Co. KGaA [Member] | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Disposal Group, Including Discontinued Operation, Consideration | 230,316 | |||
Receivable due from Divestiture of Business | (4,049) | |||
Sale of businesses | 224,481 | |||
Disposal Group, Including Discontinue Operation, Net Assets/(Liabilities) | 7,934 | |||
Foreign currency | 356 | |||
VAT and other transaction taxes, ent | (2,142) | |||
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Compugroup Medical SE & Co. KGaA [Member] | Sale of Subsidiary Gain (Loss) | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Disposal Group, Including Discontinued Operation, Consideration | 230,316 | |||
Disposal Group, including Discontinued Operation, net Assets/(Liabilities) | $ (7,934) | |||
Gain on sale of businesses | 218,349 | |||
Transaction Expenses | (5,583) | |||
Foreign Currency Adjustment | $ 1,550 |
Gain on sale of Businesses (Nar
Gain on sale of Businesses (Narrative) (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | Jul. 01, 2020 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Gain on sale of businesses | $ 0 | $ 220,523 | $ 0 | |
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Compugroup Medical SE & Co. KGaA [Member] | ||||
Discontinued Operations and Disposal Groups [Abstract] | ||||
Disposal Group, Including Discontinued Operation, Description and Timing of Disposal | On July 1, 2020, we sold certain of our business operations, primarily conducted in Germany and Spain, to affiliates of CompuGroup Medical SE & Co. KGaA ("CGM"), as a part of our portfolio management strategy. Such operations included the associates, intellectual property, client contracts, other assets, and liabilities related to our medico®, Selene®, Soarian Health Archive®, and Soarian® Integrated Care solution offerings. | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Disposal Group, Including Discontinued Operation, Description and Timing of Disposal | On July 1, 2020, we sold certain of our business operations, primarily conducted in Germany and Spain, to affiliates of CompuGroup Medical SE & Co. KGaA ("CGM"), as a part of our portfolio management strategy. Such operations included the associates, intellectual property, client contracts, other assets, and liabilities related to our medico®, Selene®, Soarian Health Archive®, and Soarian® Integrated Care solution offerings. | |||
Disposal Group, Including Discontinued Operation, Consideration | $ 230,316 | |||
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | R1 RCM Inc. [Member] | ||||
Discontinued Operations and Disposal Groups [Abstract] | ||||
Disposal Group, Including Discontinued Operation, Description and Timing of Disposal | On August 3, 2020, we sold certain of our revenue cycle outsourcing business operations to affiliates of R1 RCM Inc., as a part of our portfolio management strategy. Such operations included the associates, client contracts, certain other assets, and certain liabilities related to our commercial revenue cycle outsourcing services business. | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Disposal Group, Including Discontinued Operation, Description and Timing of Disposal | On August 3, 2020, we sold certain of our revenue cycle outsourcing business operations to affiliates of R1 RCM Inc., as a part of our portfolio management strategy. Such operations included the associates, client contracts, certain other assets, and certain liabilities related to our commercial revenue cycle outsourcing services business. | |||
Gain on sale of businesses | $ 2,000 |
Goodwill and Other Intangible_3
Goodwill and Other Intangible Assets (Schedule of Changes in Carrying Amounts of Goodwill) (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Goodwill [Roll Forward] | ||
Beginning Balance | $ 914,520 | $ 883,158 |
Goodwill, Acquired During Period | 226,232 | 33,709 |
Goodwill, Written off Related to Sale of Business Unit | (7,692) | |
Goodwill, Other Increase (Decrease) | 744 | |
Foreign currency translation adjustment and other | (9,631) | 4,601 |
Ending Balance | 1,131,121 | 914,520 |
Domestic Segment [Member] | ||
Goodwill [Roll Forward] | ||
Beginning Balance | 854,188 | 819,735 |
Goodwill, Acquired During Period | 119,709 | 33,709 |
Goodwill, Written off Related to Sale of Business Unit | 0 | |
Goodwill, Other Increase (Decrease) | 744 | |
Foreign currency translation adjustment and other | 0 | 0 |
Ending Balance | 973,897 | 854,188 |
International Segment [Member] | ||
Goodwill [Roll Forward] | ||
Beginning Balance | 60,332 | 63,423 |
Goodwill, Acquired During Period | 106,523 | 0 |
Goodwill, Written off Related to Sale of Business Unit | (7,692) | |
Goodwill, Other Increase (Decrease) | 0 | |
Foreign currency translation adjustment and other | (9,631) | 4,601 |
Ending Balance | $ 157,224 | $ 60,332 |
Goodwill and Other Intangible_4
Goodwill and Other Intangible Assets (Schedule of Finite-Lived Intangible Assets) (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | $ 1,371,418 | $ 1,150,025 |
Accumulated Amortization | 912,936 | 820,776 |
Intangible assets, net | 458,482 | 329,249 |
Customer Lists | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 636,410 | 494,615 |
Accumulated Amortization | 360,598 | 312,044 |
Purchased software | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 396,508 | 354,228 |
Accumulated Amortization | 346,381 | 337,811 |
Internal use software | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 233,438 | 207,696 |
Accumulated Amortization | 150,356 | 123,280 |
Trade Names | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 52,883 | 42,951 |
Accumulated Amortization | 33,719 | 28,961 |
Other Intangible Assets | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 52,179 | 50,535 |
Accumulated Amortization | $ 21,882 | $ 18,680 |
Goodwill and Other Intangible_5
Goodwill and Other Intangible Assets (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |||
Amortization expense | $ 95 | $ 85 | $ 114 |
Goodwill and Other Intangible_6
Goodwill and Other Intangible Assets (Schedule of Estimated Aggregate Amortization Expense) (Details) $ in Thousands | Dec. 31, 2021USD ($) |
Goodwill and Intangible Assets Disclosure [Abstract] | |
2022 | $ 96,281 |
2023 | 86,863 |
2024 | 79,985 |
2025 | 38,916 |
2026 | $ 20,769 |
Indebtedness (Schedule of Indeb
Indebtedness (Schedule of Indebtedness Outstanding) (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Debt Instrument [Line Items] | ||
Long-term Debt | $ 1,836,662 | $ 1,336,662 |
Debt Issuance Costs, Noncurrent, Net | (406) | (593) |
Long-term debt | 1,611,256 | 1,336,069 |
Long-term Debt, Net of Debt Issuance Costs | 1,836,256 | 1,336,069 |
Long-term Debt, Current Maturities | 225,000 | 0 |
Line of Credit [Member] | ||
Debt Instrument [Line Items] | ||
Long-term Debt | $ 600,000 | 600,000 |
Debt Instrument, Maturity Date | Dec. 30, 2026 | |
Senior Notes - Series 2021-A due March 24, 2026 | ||
Debt Instrument [Line Items] | ||
Long-term Debt | $ 100,000 | 0 |
Debt Instrument, Maturity Date | Mar. 24, 2026 | |
Senior Notes - Series 2021-B due March 24, 2031 | ||
Debt Instrument [Line Items] | ||
Long-term Debt | $ 400,000 | 0 |
Debt Instrument, Maturity Date | Mar. 24, 2031 | |
Senior Notes - Series 2020-A due March 11, 2030 | ||
Debt Instrument [Line Items] | ||
Long-term Debt | $ 300,000 | 300,000 |
Debt Instrument, Maturity Date | Mar. 11, 2030 | |
Senior Notes - Series 2015-A due February 15, 2022 | ||
Debt Instrument [Line Items] | ||
Long-term Debt | $ 225,000 | 225,000 |
Debt Instrument, Maturity Date | Feb. 15, 2022 | |
Senior Notes - Series 2015-B due February 14, 2025 | ||
Debt Instrument [Line Items] | ||
Long-term Debt | $ 200,000 | 200,000 |
Debt Instrument, Maturity Date | Feb. 14, 2025 | |
Other [Member] | ||
Debt Instrument [Line Items] | ||
Long-term Debt | $ 11,662 | $ 11,662 |
Debt Instrument, Maturity Date | Sep. 1, 2025 |
Indebtedness (Details)
Indebtedness (Details) - USD ($) $ in Thousands | Jan. 19, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | Dec. 29, 2018 | Jan. 29, 2015 |
Debt Instrument [Line Items] | |||||||
Repayment of long-term debt | $ 0 | $ 2,500 | $ 0 | ||||
Long-term Debt | $ 1,836,662 | 1,336,662 | |||||
Debt Instrument, Covenant Compliance | As of December 31, 2021, we were in compliance with all debt covenants | ||||||
General Discussion of Derivative Instruments and Hedging Activities | We are exposed to market risk from fluctuations in the variable interest rates on outstanding indebtedness under our Credit Agreement. In order to manage this exposure, we have entered into an interest rate swap agreement, with an initial notional amount of $600 million, to hedge the variability of cash flows associated with such interest obligations through May 2024. The interest rate swap has an effective start date of May 13, 2019, and is designated as a cash flow hedge, which effectively fixes the interest rate on the hedged indebtedness under our Credit Agreement at 3.06% through May 2024 | ||||||
Derivative, Fair Value, Net | $ 17,000 | $ 37,000 | |||||
Derivatives, Methods of Accounting, Hedging Derivatives [Policy Text Block] | Our interest rate swap agreement is accounted for in accordance with ASC Topic 815, Derivatives and Hedging . Such agreement is designated as a cash flow hedge and considered to be highly effective under hedge accounting principles. Therefore, the swap agreement is recognized in our consolidated balance sheets as either an asset or liability, measured at fair value. Changes in the fair value of the swap agreement are initially recorded in accumulated other comprehensive loss, net and then subsequently recognized in our consolidated statements of operations in the periods in which earnings are affected by the hedged item. All cash flows associated with the swap agreement are classified as operating activities in our consolidated statements of cash flows | ||||||
Line of Credit Facility, Description | On December 30, 2021, we amended and restated our revolving credit facility by entering into a Fourth Amended and Restated Credit Agreement (the "Credit Agreement") with a syndicate of lenders. The Credit Agreement is a five-year revolving credit facility expiring on December 30, 2026, with two one-year extension options that are subject to lender approval. The Credit Agreement includes: (a) a revolving credit loan facility of up to $1.225 billion at any time outstanding, and (b) a letter of credit facility of up to $200 million at any time outstanding (which is a sub-facility of the $1.225 billion revolving credit loan facility). The Credit Agreement also includes an accordion feature allowing an increase of the credit facility of up to an additional $500 million ($1.725 billion in the aggregate) at any time outstanding, subject to lender participation and the satisfaction of specified conditions. Prepayment of borrowings outstanding under the Credit Agreement is permitted at any time. Proceeds may be used for working capital and general corporate purposes, including but not limited to certain business acquisitions and purchases under our share repurchase programs. The Credit Agreement provides certain restrictions on our ability to borrow, incur liens, sell assets and pay dividends, and contains certain leverage and interest coverage covenants | ||||||
Line of Credit Facility, Interest Rate Description | Generally, interest on revolving credit loans is payable at a variable rate based on LIBOR, prime, or the U.S. federal funds rate, plus a spread that varies depending on leverage ratios maintained. Unused commitment, letter of credit, and other fees are also payable under the Credit Agreement | ||||||
Line of Credit Facility, Interest Rate at Period End | 0.90% | 0.95% | |||||
Letters of Credit Outstanding, Amount | $ 18,000 | ||||||
Line of Credit Facility, Remaining Borrowing Capacity | $ 607,000 | ||||||
Subsequent Event [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Subsequent Event, Description | On December 20, 2021, we entered into an Agreement and Plan of Merger (as it may be amended or supplemented from time to time, the "Merger Agreement") with Cedar Acquisition Corporation ("Merger Subsidiary"), which is a wholly owned subsidiary of OC Acquisition LLC ("Parent"), Parent, which is a wholly owned subsidiary of Oracle Corporation ("Oracle"), and (solely with respect to performance of its obligations set forth in certain specified sections thereof) Oracle. Pursuant to the Merger Agreement, on January 19, 2022, Oracle commenced a cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of our common stock for a purchase price of $95.00 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. If the Offer is completed, Merger Subsidiary will merge with and into Cerner (the "Merger") and we will become a wholly owned indirect subsidiary of Oracle. As a result of the Merger, the shares of our common stock will cease to be publicly held. Completion of the Merger is subject to certain conditions, including but not limited to, a) shareholders holding a majority of the outstanding shares of our common stock tendering their shares in the Offer, and b) receipt of certain regulatory approvals, including the expiration or termination of the waiting periods or the obtaining of the required affirmative approvals applicable to the transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and certain foreign antitrust and foreign direct investment laws. We have agreed to various customary covenants and agreements in the Merger Agreement, including with respect to the operation of our business prior to the closing of the transaction, such as restrictions on making certain acquisitions and divestitures, entering into certain contracts, incurring certain indebtedness and making certain capital expenditures, paying dividends in excess of our regular quarterly dividend, issuing or repurchasing stock and taking other specified actions. | On February 15, 2022, we repaid our $225 million of Series 2015-A Notes due February 15, 2022. | |||||
Senior Notes [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Face Amount | $ 500,000 | ||||||
Debt Instrument, Restrictive Covenants | The Master Note Purchase Agreement contains certain leverage and interest coverage ratio covenants and provides certain restrictions on our ability to borrow, incur liens, sell assets, and other customary terms | ||||||
Line of Credit [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Maturity Date | Dec. 30, 2026 | ||||||
Long-term Debt | $ 600,000 | $ 600,000 | |||||
2014 Shelf Agreement [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Aggregate Principle Amount | 1,500,000 | ||||||
Debt Instrument, Amount Uncommitted and Available for Sale | $ 1,000,000 | ||||||
Other [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Maturity Date | Sep. 1, 2025 | ||||||
Long-term Debt | $ 11,662 | 11,662 | |||||
Senior Notes - Series 2015-A due February 15, 2022 | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Face Amount | $ 225,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 3.18% | ||||||
Debt Instrument, Frequency of Periodic Payment | payable semiannually | ||||||
Debt Instrument, Date of First Required Payment | Aug. 15, 2015 | ||||||
Debt Instrument, Maturity Date | Feb. 15, 2022 | ||||||
Long-term Debt | $ 225,000 | 225,000 | |||||
Senior Notes - Series 2015-B due February 14, 2025 | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Face Amount | $ 200,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 3.58% | ||||||
Debt Instrument, Maturity Date | Feb. 14, 2025 | ||||||
Long-term Debt | $ 200,000 | 200,000 | |||||
Senior Notes - Series 2015-C due February 15, 2022 [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Face Amount | $ 75,000 | ||||||
Debt Instrument, Maturity Date | Feb. 15, 2022 | ||||||
Repayment of long-term debt | $ 75,000 | ||||||
Senior Notes - Series 2020-A due March 11, 2030 | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Face Amount | $ 300,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 2.50% | ||||||
Debt Instrument, Frequency of Periodic Payment | payable semiannually | ||||||
Debt Instrument, Date of First Required Payment | Sep. 11, 2020 | ||||||
Debt Instrument, Maturity Date | Mar. 11, 2030 | ||||||
Debt Instrument, Restrictive Covenants | The Series 2021 Senior Notes and Series 2020-A Notes are subject to the terms of the 2019 Shelf Agreement, which contains customary events of default and covenants related to limitations on indebtedness and transactions with affiliates and the maintenance of certain financial ratios. | ||||||
Long-term Debt | $ 300,000 | 300,000 | |||||
2019 Shelf Agreement [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Aggregate Principle Amount | 1,800,000 | ||||||
Debt Instrument, Amount Uncommitted and Available for Sale | 1,000,000 | ||||||
Senior Notes - Series 2021-A due March 24, 2026 | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Face Amount | $ 100,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 2.00% | ||||||
Debt Instrument, Maturity Date | Mar. 24, 2026 | ||||||
Long-term Debt | $ 100,000 | 0 | |||||
Senior Notes - Series 2021-B due March 24, 2031 | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Face Amount | $ 400,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 2.59% | ||||||
Debt Instrument, Maturity Date | Mar. 24, 2031 | ||||||
Long-term Debt | $ 400,000 | $ 0 | |||||
Senior Notes - Series 2021 | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Face Amount | $ 500,000 | ||||||
Debt Instrument, Frequency of Periodic Payment | payable semiannually | ||||||
Debt Instrument, Date of First Required Payment | Sep. 24, 2021 |
Indebtedness (Schedule of Futur
Indebtedness (Schedule of Future Maturities of Indebtedness) (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | $ 1,836,662 | $ 1,336,662 |
2022 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 225,000 | |
2023 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 0 | |
2024 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 0 | |
2025 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 211,662 | |
2026 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 700,000 | |
2027 and thereafter | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 700,000 | |
Line of Credit [Member] | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 600,000 | |
Line of Credit [Member] | 2022 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 0 | |
Line of Credit [Member] | 2023 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 0 | |
Line of Credit [Member] | 2024 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 0 | |
Line of Credit [Member] | 2025 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 0 | |
Line of Credit [Member] | 2026 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 600,000 | |
Line of Credit [Member] | 2027 and thereafter | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 0 | |
Senior Notes [Member] | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 1,225,000 | |
Senior Notes [Member] | 2022 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 225,000 | |
Senior Notes [Member] | 2023 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 0 | |
Senior Notes [Member] | 2024 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 0 | |
Senior Notes [Member] | 2025 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 200,000 | |
Senior Notes [Member] | 2026 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 100,000 | |
Senior Notes [Member] | 2027 and thereafter | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 700,000 | |
Other [Member] | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 11,662 | |
Other [Member] | 2022 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 0 | |
Other [Member] | 2023 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 0 | |
Other [Member] | 2024 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 0 | |
Other [Member] | 2025 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 11,662 | |
Other [Member] | 2026 | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | 0 | |
Other [Member] | 2027 and thereafter | ||
Schedule of Future Maturities of Indebtedness [Line Items] | ||
Long-term Debt | $ 0 |
Fair Value Measurements (Narrat
Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Fair Value Disclosures [Abstract] | ||
Fair Value Measurements, Valuation Processes, Description | We estimate the fair value of our long-term, fixed rate debt using a Level 3 discounted cash flow analysis based on current borrowing rates for debt with similar maturities. We estimate the fair value of our long-term, variable rate debt using a Level 3 discounted cash flow analysis based on LIBOR rate forward curves | |
Fair value of long-term debt, including current maturities | $ 1,870 | $ 1,360 |
Unsecured Long-term Debt, Noncurrent | $ 1,830 | $ 1,330 |
Fair Value Measurements Fair Va
Fair Value Measurements Fair Value, Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | $ 551,261 | $ 717,334 |
Level 1 [Member] | Money market funds [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 149,429 | 40,027 |
Level 1 [Member] | Time deposits [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 0 | |
Level 1 [Member] | Commercial paper [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 0 | |
Level 2 [Member] | Money market funds [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 0 | |
Level 2 [Member] | Time deposits [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 35,342 | 36,756 |
Level 2 [Member] | Commercial paper [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 77,850 | 61,000 |
Level 2 [Member] | Government and corporate bonds [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 5,000 | |
Fair Value, Inputs, Level 3 [Member] | Money market funds [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 0 | |
Fair Value, Inputs, Level 3 [Member] | Time deposits [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 0 | |
Fair Value, Inputs, Level 3 [Member] | Commercial paper [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 0 | |
Short-term investments [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 252,622 | 442,473 |
Short-term investments [Member] | Level 1 [Member] | Time deposits [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | |
Short-term investments [Member] | Level 1 [Member] | Commercial paper [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | |
Short-term investments [Member] | Level 1 [Member] | Government and corporate bonds [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | |
Short-term investments [Member] | Level 2 [Member] | Time deposits [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 25,598 | 28,302 |
Short-term investments [Member] | Level 2 [Member] | Commercial paper [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 56,986 | 263,993 |
Short-term investments [Member] | Level 2 [Member] | Government and corporate bonds [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 170,038 | 150,178 |
Short-term investments [Member] | Fair Value, Inputs, Level 3 [Member] | Time deposits [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | |
Short-term investments [Member] | Fair Value, Inputs, Level 3 [Member] | Commercial paper [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | |
Short-term investments [Member] | Fair Value, Inputs, Level 3 [Member] | Government and corporate bonds [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | |
Long-term investments [Member] | Level 1 [Member] | Government and corporate bonds [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | |
Long-term investments [Member] | Level 2 [Member] | Government and corporate bonds [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | $ 31,018 | 137,078 |
Long-term investments [Member] | Fair Value, Inputs, Level 3 [Member] | Government and corporate bonds [Member] | Fair Value, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | $ 0 |
Contingencies Contingencies (Na
Contingencies Contingencies (Narrative) (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Steward Health Care System LLC | |
Loss Contingencies [Line Items] | |
Loss Contingency, Management's Assessment and Process | On May 16, 2019, Steward Health Care System LLC ("Steward") filed a lawsuit in the Chancery Court for Davidson County, Tennessee against the Company. The Company believes Steward's allegations arise out of Steward's disinterest in following the contract between the Company and Steward's predecessor for clinical and financial software and services after Steward closed on its acquisition of the predecessor. The Company has filed a counterclaim against Steward seeking recovery of more than $42 million in unpaid invoices owed to the Company. The Company believes the dispute is in the ordinary course of business and the damages Steward asserts lack both factual and causal support. Steward has recently asserted that its damages are $300 million and advised the Company that it will seek to treble the damages. We have not concluded that a material loss related to the Steward allegations is probable, nor have we accrued a liability related to these claims. Although we believe a loss could be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss with respect to the potential damages given that the dispute is in the discovery process. We will continue to vigorously defend against these claims, and we continue to believe that we have valid grounds for recovery of the disputed client receivables. However, there can be no assurances as to the outcome of the dispute. |
Astria Health | |
Loss Contingencies [Line Items] | |
Loss Contingency, Management's Assessment and Process | On March 22, 2021, Astria Health ("Astria") filed an adversary proceeding in the United States Bankruptcy Court, Eastern District of Washington against the Company. Astria's allegations largely arise out of the Company's provision of revenue cycle services in 2018 and 2019. The Company believes the dispute is in the ordinary course of business and the factual allegations and the damages asserted lack both factual and causal support. Astria has recently claimed damages of $96 million. We have not concluded that a material loss related to the Astria allegations is probable, nor have we accrued a liability related to these claims beyond reserving certain bankruptcy-related outstanding invoices. Although we believe a loss could be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss with respect to the potential damages given that expert discovery is not yet complete. We will continue to vigorously defend against this claim. However, there can be no assurances as to the outcome of the dispute. |
Other Income (Schedule of Inter
Other Income (Schedule of Interest Income and Expense) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Nonoperating Income (Expense) [Abstract] | |||
Interest income | $ 25,975 | $ 28,901 | $ 38,227 |
Interest expense | (43,474) | (29,080) | (14,469) |
Gain on sale of equity investment | 0 | 75,834 | 15,509 |
Unrealized gain on equity investment | 0 | 0 | 14,112 |
Other | 8,683 | 1,251 | 464 |
Other income, net | $ (8,816) | $ 76,906 | $ 53,843 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Operating Loss Carryforwards [Line Items] | |||
Valuation Allowance | $ 9,575 | $ 3,384 | |
Cumulative undistributed earnings of foreign subsidiaries | 115,000 | ||
Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries | $ 6,000 | ||
Effective tax rate | 21.00% | 21.00% | 19.00% |
Federal statutory income tax rate | 21.00% | ||
Unrecognized Tax Benefits that Would Impact Effective Tax Rate | $ 29,000 | ||
Change in unrecognized tax benefits in next 12 months | It is reasonably possible that our unrecognized tax benefits may decrease by up to $12 million within the next twelve months. | ||
Last year examined | Our federal returns have been examined by the Internal Revenue Service through 2016. Our federal returns are open for examination for 2017 and thereafter. We have various state and foreign returns under examination. | ||
Accrued interest related to unrecognized tax benefits | $ 6,000 | $ 5,000 | |
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense | 1,000 | ||
Deferred Tax Assets, Increase in Valuation Allowance | (6,000) | ||
Foreign Tax Authority [Member] | No Expiration Date [Member] | |||
Operating Loss Carryforwards [Line Items] | |||
Operating Loss Carryforwards | 19,000 | ||
State and Local Jurisdiction [Member] | |||
Operating Loss Carryforwards [Line Items] | |||
Tax Credit Carryforward, Amount | $ 8,000 | ||
Tax Credit Carryforward, Expiration Date | Dec. 31, 2030 |
Income Taxes (Schedule of Compo
Income Taxes (Schedule of Components of Income Tax Expense (Benefit)) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Current: | |||
Federal | $ 95,526 | $ 131,741 | $ 45,575 |
State | 20,968 | 30,565 | 13,429 |
Foreign | 20,019 | 47,577 | 14,929 |
Total current expense | 136,513 | 209,883 | 73,933 |
Deferred: | |||
Federal | (2,646) | (4,469) | 30,353 |
State | 7,568 | (96) | 11,747 |
Foreign | 2,429 | 6,067 | 9,025 |
Total deferred expense (benefit) | 7,351 | 1,502 | 51,125 |
Total income tax expense | $ 143,864 | $ 211,385 | $ 125,058 |
Income Taxes (Schedule of Defer
Income Taxes (Schedule of Deferred Tax Assets and Deferred Tax Liabilities) (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Deferred tax assets: | ||
Accrued expenses | $ 56,913 | $ 63,080 |
Tax credits and separate return net operating losses | 12,939 | 17,976 |
Deferred Tax Asset, Contract and service revenues and costs | 28,001 | 9,383 |
Share based compensation | 30,216 | 49,650 |
Deferred Tax Assets, Lease Liability | 21,548 | 23,928 |
Other | 15,070 | 17,554 |
Gross deferred tax assets | 164,687 | 181,571 |
Valuation Allowance | (9,575) | (3,384) |
Total deferred tax assets | 155,112 | 178,187 |
Deferred tax liabilities: | ||
Software development costs | (265,384) | (270,041) |
Depreciation and amortization | (204,203) | (204,568) |
Prepaid expenses | (39,499) | (37,547) |
Deferred Tax Liability, Lease Right-of-use Asset | (17,900) | (20,639) |
Other | (11,253) | (9,260) |
Total deferred tax liabilities | (538,239) | (542,055) |
Net deferred tax liability | $ (383,127) | $ (363,868) |
Income Taxes (Schedule of Effec
Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Income Tax Disclosure [Abstract] | |||
Tax expense at statutory rates | $ 146,887 | $ 208,209 | $ 137,447 |
State income tax, net of federal benefit | 15,938 | 24,234 | 18,561 |
Tax credits | (19,739) | (21,254) | (22,750) |
Foreign rate differential | (8,940) | 1,973 | (6,328) |
Share-based compensation | 7,351 | (1,303) | (8,090) |
Permanent differences | 1,053 | (6,534) | 3,278 |
Other, net | 1,314 | 6,060 | 2,940 |
Total income tax expense | $ 143,864 | $ 211,385 | $ 125,058 |
Income Taxes (Schedule of Unrec
Income Taxes (Schedule of Unrecognized Tax Benefits Rollforward) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Unrecognized tax benefit - beginning balance | $ 22,204 | $ 19,125 | $ 18,688 |
Gross decreases - tax positions in prior periods | (7,252) | (3,964) | (2,383) |
Gross increases - tax positions in prior periods | 8,235 | 312 | 1,220 |
Gross increases - tax positions in current year | 6,479 | 6,595 | 1,607 |
Acquisitions | 5,112 | 0 | 0 |
Increase resulting from currency translation | (136) | ||
Decrease resulting from currency translation | 439 | 7 | |
Unrecognized tax benefit - ending balance | $ 34,339 | $ 22,204 | $ 19,125 |
Income Taxes Foreign Income (De
Income Taxes Foreign Income (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Income Tax - Foreign Disclosure [Abstract] | |||
Income (Loss) from Continuing Operations before Income Taxes, Foreign | $ 136 | $ 208 | $ 109 |
Earnings Per Share (Reconciliat
Earnings Per Share (Reconciliation Of The Numerators And The Denominators Of The Basic And Diluted Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Earnings Per Share [Abstract] | |||
Income available to common shareholders, basic | $ 555,596 | $ 780,088 | $ 529,454 |
Income available to common shareholders including assumed conversions, diluted | $ 555,596 | $ 780,088 | $ 529,454 |
Basic weighted average shares outstanding | 298,725 | 306,669 | 318,229 |
Stock options, non-vested shares and share units | 2,548 | 2,467 | 3,006 |
Diluted weighted average shares outstanding | 301,273 | 309,136 | 321,235 |
Basic earnings per share | $ 1.86 | $ 2.54 | $ 1.66 |
Diluted earnings per share | $ 1.84 | $ 2.52 | $ 1.65 |
Earnings Per Share (Narrative)
Earnings Per Share (Narrative) (Details) - $ / shares shares in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Earnings Per Share [Abstract] | |||
Antidilutive securities excluded from computation of earnings per share, amount | 0.4 | 4.1 | 9.6 |
Antidilutive securities excluded from computation of earnings per share, exercise price, lower range limit | $ 52.32 | $ 52.32 | $ 52.32 |
Antidilutive securities excluded from computation of earnings per share, exercise price, upper range limit | $ 76.49 | $ 76.49 | $ 75.83 |
Share-Based Compensation (Narra
Share-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares available for awards | 12.5 | ||
Contractual term of options | 10 years | ||
Associate stock purchase plan discount | 15.00% | ||
Authorized preferred shares | 1 | ||
Par value per share of preferred stock | $ 0.01 | ||
Stock Repurchase Program, Remaining Authorized Repurchase Amount | $ 3,180 | ||
Dividends Payable | $ 81 | $ 69 | |
Treasury Stock, Shares, Acquired | 20 | 10.6 | 18.8 |
Treasury stock purchases | $ 1,500 | $ 757 | $ 1,300 |
Stock Repurchase Program Expiration Date | Dec. 31, 2023 | ||
2021 Share Repurchase Program | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock Repurchase Program, Authorized Amount | $ 3,750 | ||
2017 Share Repurchase Program | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock Repurchase Program, Authorized Amount | 3,700 | ||
Stock Options [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $ 14 | ||
Period of recognition for remaining share-based compensation expense | 1 year 2 months 12 days | ||
Restricted Stock [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total unrecognized compensation cost | $ 195 | ||
Period of recognition for remaining share-based compensation expense | 1 year 11 months 26 days | ||
Minimum [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Typical vesting period for option awards | 4 years | ||
Maximum [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Typical vesting period for option awards | 5 years |
Share-Based Compensation (Sched
Share-Based Compensation (Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions) (Details) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 28, 2019 | |
Share-based Payment Arrangement [Abstract] | ||
Expected volatility (%) | 24.50% | 25.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 1.00% | 1.00% |
Expected term (yrs) | 6 years | 7 years |
Risk-free rate (%) | 1.10% | 2.40% |
Share-Based Compensation (Sch_2
Share-Based Compensation (Schedule Of Stock Options Activity) (Details) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended |
Dec. 31, 2021USD ($)$ / sharesshares | |
Share-based Payment Arrangement [Abstract] | |
Outstanding at beginning of year, number of shares | shares | 10,204 |
Outstanding at beginning of year, weighted-average exercise price | $ / shares | $ 58.59 |
Granted, number of shares | shares | 0 |
Granted, weighted-average exercise price | $ / shares | $ 0 |
Exercised, number of shares | shares | (5,276) |
Exercised, weighted-average exercise price | $ / shares | $ 57.75 |
Forfeited and expired, number of shares | shares | (258) |
Forfeited and expired, weighted-average exercise price | $ / shares | $ 57.32 |
Outstanding end of year, number of shares | shares | 4,670 |
Outstanding at end of year, weighted-average exercise price | $ / shares | $ 59.61 |
Outstanding at end of year, aggregate intrinsic value | $ | $ 155,331 |
Outstanding at end of year, weighted-average remaining contractual term | 4 years 7 months 20 days |
Exercisable at end of year, number of shares | shares | 3,365 |
Exercisable at end of year, weighted-average exercise price | $ / shares | $ 58.85 |
Exercisable at end of year, aggregate intrinsic value | $ | $ 114,503 |
Exercisable at end of year, weighted-average remaining contractual term | 4 years 7 days |
Share-Based Compensation (Sch_3
Share-Based Compensation (Schedule of Weighted Average Grant Date Fair Values of Options Granted in Period and Other Disclosures) (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Share-based Payment Arrangement [Abstract] | |||
Weighted-average grant date fair value | $ 0 | $ 16.64 | $ 17.51 |
Total intrinsic value of options exercised | $ 110,916 | $ 115,607 | $ 155,202 |
Cash received from exercise of stock options | 304,078 | 253,605 | 258,036 |
Share-based Payment Arrangement, Exercise of Option, Tax Benefit | $ 24,791 | $ 27,103 | $ 36,629 |
Share-Based Compensation (Sch_4
Share-Based Compensation (Schedule Of Non-Vested Shares Activity) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Granted, weighted-average grant date fair value | $ 76.01 | $ 70.12 | $ 66.49 |
Total fair value of shares vested during the year | $ 202,543 | $ 70,355 | $ 30,558 |
Restricted Stock [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition | 1 year 11 months 26 days | ||
Outstanding at beginning of year, number of shares | 4,131 | ||
Outstanding at beginning of year, weighted-average grant date fair value | $ 68.05 | ||
Granted, number of shares | 2,872 | ||
Granted, weighted-average grant date fair value | $ 76.01 | ||
Vested, number of shares | (2,681) | ||
Vested, weighted-average grant date fair value | $ 68.24 | ||
Forfeited, number of shares | (678) | ||
Forfeited, weighted-average grant date fair value | $ 72.53 | ||
Outstanding at end of year, number of shares | 3,644 | 4,131 | |
Outstanding at end of year, weighted-average grant date fair value | $ 73.35 | $ 68.05 |
Share-Based Compensation (Compe
Share-Based Compensation (Compensation Expense Recognized In The Condensed Consolidated Statements Of Operations) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Amounts charged against earnings, before income tax benefit | $ 197,241 | $ 154,060 | $ 109,284 |
Amount of related income tax benefit recognized in earnings | 38,623 | 30,775 | 20,967 |
Stock option and non-vested share compensation expense | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Amounts charged against earnings, before income tax benefit | 195,654 | 153,449 | 103,641 |
Associate stock purchase plan expense | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Amounts charged against earnings, before income tax benefit | 5,786 | 5,478 | 6,053 |
Amounts capitalized in software development costs, net of amortization | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Amounts charged against earnings, before income tax benefit | $ (4,199) | $ (4,867) | $ (410) |
Share-Based Compensation Schedu
Share-Based Compensation Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | Dec. 29, 2018 | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Accumulated other comprehensive loss, net | $ (127,558) | $ (120,804) | ||
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Accumulated other comprehensive loss, net | (114,630) | (93,450) | $ (106,347) | $ (102,939) |
OCI, before Reclassifications, Net of Tax, Attributable to Parent | (21,180) | 12,897 | (3,408) | |
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent | 0 | 0 | 0 | |
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Accumulated other comprehensive loss, net | (12,961) | (27,788) | (12,578) | 0 |
OCI, before Reclassifications, Net of Tax, Attributable to Parent | 4,241 | (23,687) | (13,078) | |
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent | 10,586 | 8,477 | 500 | |
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Accumulated other comprehensive loss, net | 33 | 434 | 265 | (613) |
OCI, before Reclassifications, Net of Tax, Attributable to Parent | (440) | 194 | 901 | |
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent | 39 | (25) | (23) | |
AOCI Attributable to Parent [Member] | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Accumulated other comprehensive loss, net | (127,558) | (120,804) | (118,660) | $ (103,552) |
OCI, before Reclassifications, Net of Tax, Attributable to Parent | (17,379) | (10,596) | (15,585) | |
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent | $ 10,625 | $ 8,452 | $ 477 |
Share-Based Compensation Reclas
Share-Based Compensation Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | Dec. 29, 2018 | |
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Accumulated other comprehensive loss, net | $ (127,558) | $ (120,804) | ||
Other income, net | (8,816) | 76,906 | $ 53,843 | |
Income Tax Expense (Benefit) | 143,864 | 211,385 | 125,058 | |
Net earnings | 555,596 | 780,088 | 529,454 | |
Reclassification out of Accumulated Other Comprehensive Income [Member] | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Net earnings | (10,625) | (8,452) | (477) | |
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Accumulated other comprehensive loss, net | (114,630) | (93,450) | (106,347) | $ (102,939) |
OCI, before Reclassifications, Net of Tax, Attributable to Parent | (21,180) | 12,897 | (3,408) | |
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent | 0 | 0 | 0 | |
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Accumulated other comprehensive loss, net | (12,961) | (27,788) | (12,578) | 0 |
OCI, before Reclassifications, Net of Tax, Attributable to Parent | 4,241 | (23,687) | (13,078) | |
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent | 10,586 | 8,477 | 500 | |
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Other income, net | (13,150) | (10,622) | (624) | |
Income Tax Expense (Benefit) | 2,564 | 2,145 | 124 | |
Net earnings | (10,586) | (8,477) | (500) | |
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Accumulated other comprehensive loss, net | 33 | 434 | 265 | (613) |
OCI, before Reclassifications, Net of Tax, Attributable to Parent | (440) | 194 | 901 | |
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent | 39 | (25) | (23) | |
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Other income, net | (48) | 31 | 29 | |
Income Tax Expense (Benefit) | 9 | (6) | (6) | |
Net earnings | (39) | 25 | 23 | |
AOCI Attributable to Parent [Member] | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Accumulated other comprehensive loss, net | (127,558) | (120,804) | (118,660) | $ (103,552) |
OCI, before Reclassifications, Net of Tax, Attributable to Parent | (17,379) | (10,596) | (15,585) | |
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent | $ 10,625 | $ 8,452 | $ 477 |
Share-Based Compensation Cash D
Share-Based Compensation Cash Dividend Activity (Details) - $ / shares | 3 Months Ended | ||||||||||
Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 28, 2019 | Sep. 28, 2019 | Jun. 29, 2019 | |
Text Block [Abstract] | |||||||||||
Dividends Payable, Date Declared | Dec. 9, 2021 | Sep. 9, 2021 | May 19, 2021 | Mar. 25, 2021 | Dec. 10, 2020 | Sep. 10, 2020 | May 21, 2020 | Mar. 19, 2020 | Dec. 12, 2019 | Sep. 10, 2019 | May 29, 2019 |
Dividends Payable, Date of Record | Dec. 27, 2021 | Sep. 27, 2021 | Jun. 28, 2021 | Apr. 6, 2021 | Dec. 28, 2020 | Sep. 25, 2020 | Jun. 5, 2020 | Apr. 3, 2020 | Dec. 27, 2019 | Sep. 25, 2019 | Jun. 18, 2019 |
Dividends Payable, Date to be Paid | Jan. 11, 2022 | Oct. 12, 2021 | Jul. 13, 2021 | Apr. 20, 2021 | Jan. 12, 2021 | Oct. 13, 2020 | Jul. 17, 2020 | Apr. 17, 2020 | Jan. 9, 2020 | Oct. 9, 2019 | Jul. 26, 2019 |
Dividends Payable, Amount Per Share | $ 0.27 | $ 0.22 | $ 0.22 | $ 0.22 | $ 0.22 | $ 0.18 | $ 0.18 | $ 0.18 | $ 0.18 | $ 0.18 | $ 0.18 |
Foundations Retirement Plan (De
Foundations Retirement Plan (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Discretionary Match [Member] | |||
Defined Contribution Plan Disclosure [Line Items] | |||
Defined Contribution Plan, Cost | $ 38 | $ 61 | $ 59 |
Commitments (Schedule of Aggreg
Commitments (Schedule of Aggregate Future Payments for Purchase Commitments) (Details) $ in Thousands | Dec. 31, 2021USD ($) |
Unrecorded Unconditional Purchase Obligation, Fiscal Year Maturity [Abstract] | |
2022 | $ 54,308 |
2023 | 54,308 |
2024 | 40,933 |
2025 | 45,819 |
2026 | 52,054 |
2027 and thereafter | 368,882 |
Total | $ 616,304 |
Segment Reporting Segment Repor
Segment Reporting Segment Reporting (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Segment Reporting [Abstract] | |
Segment Reporting, Factors Used to Identify Entity's Reportable Segments | We have two operating segments, Domestic and International. Revenues are derived primarily from the sale of clinical, financial and administrative information solutions and services. The cost of revenues includes the cost of third-party consulting services, computer hardware, devices and sublicensed software purchased from manufacturers for delivery to clients. It also includes the cost of hardware maintenance and sublicensed software support subcontracted to the manufacturers. Operating expenses incurred by the geographic business segments consist of sales and client service expenses including salaries of sales and client service personnel, expenses associated with our managed services business, marketing expenses, communications expenses and unreimbursed travel expenses. "Other" includes expenses that have not been allocated to the operating segments, such as software development, general and administrative expenses, certain organizational restructuring and other expense, share-based compensation expense, and certain amortization and depreciation. "Other" also includes gains or losses recognized on the divestiture of businesses. Performance of the segments is assessed at the operating earnings level by our chief operating decision maker, who is our Chief Executive Officer. Items such as interest, income taxes, capital expenditures and total assets are managed at the consolidated level and thus are not included in our operating segment disclosures. Accounting policies for each of the reportable segments are the same as those used on a consolidated basis. |
Segment Reporting (Summary Of T
Segment Reporting (Summary Of The Operating Information) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 28, 2019 | |
Segment Reporting Information [Line Items] | |||
Revenue | $ 5,764,824 | $ 5,505,788 | $ 5,692,598 |
Cost of revenues | 1,001,017 | 932,941 | 1,071,041 |
Operating expenses | 4,055,531 | 3,878,803 | 4,020,888 |
Total costs and expenses | 5,056,548 | 4,811,744 | 5,091,929 |
Gain on sale of businesses | 0 | 220,523 | 0 |
Operating earnings | 708,276 | 914,567 | 600,669 |
Domestic Segment [Member] | |||
Segment Reporting Information [Line Items] | |||
Revenue | 5,044,629 | 4,879,769 | 5,038,127 |
Cost of revenues | 887,343 | 854,574 | 967,035 |
Operating expenses | 2,358,897 | 2,339,624 | 2,398,422 |
Total costs and expenses | 3,246,240 | 3,194,198 | 3,365,457 |
Gain on sale of businesses | 0 | ||
Operating earnings | 1,798,389 | 1,685,571 | 1,672,670 |
International Segment [Member] | |||
Segment Reporting Information [Line Items] | |||
Revenue | 720,195 | 626,019 | 654,471 |
Cost of revenues | 113,674 | 78,367 | 104,006 |
Operating expenses | 277,308 | 242,991 | 276,914 |
Total costs and expenses | 390,982 | 321,358 | 380,920 |
Gain on sale of businesses | 0 | ||
Operating earnings | 329,213 | 304,661 | 273,551 |
Other | |||
Segment Reporting Information [Line Items] | |||
Operating expenses | 1,419,326 | 1,296,188 | 1,345,552 |
Total costs and expenses | 1,419,326 | 1,296,188 | 1,345,552 |
Gain on sale of businesses | 220,523 | ||
Operating earnings | $ (1,419,326) | $ (1,075,665) | $ (1,345,552) |